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ABSTRACT 
Cancer is the second leading cause of death. Although it is already validated the use of 
techniques such as radiotherapy, immunotherapy and chemotherapy, in the last decade the 
medical community has focused on the research of less invasive drugs, through the 
identification of new anticancer agents, as well as by the design of an innovative system 
for the drug delivery, like the liposomes, that allow the protection of the active principle 
until the achievement of molecular target, reducing the toxic effects. Among the new 
anticancer agents currently in clinical trials, there are the ruthenium-based compounds, 
NAMI-A and KP1019. These have emerged as promising alternatives to platinum 
compounds (Cisplatin, Oxaliplatin, Carboplatin) that constitute still an important class of 
chemotherapeutics, whose limit is the high toxicity. Although ruthenium and platinum 
belong to the same chemical series, the ruthenium complexes showed anticancer and/or 
antimetastatic activity, associated with fewer side effects. The difference between the 
derivatives of ruthenium and platinum is probably due to their different pharmacodynamics 
that, if is well known for Cisplatin and its analogs, it is not yet completely clarified for the 
other metal complexes. Also, the chemical characteristics like the redox potential, the 
charges and the lipophilicity are very different among the various classes of metal-based 
compounds, reflecting their different biological effects.  
In this context, my Ph.D. aim was the validation of new metal-based agents for the cancer 
therapy; in particular I analyzed two different classes of compounds:  
- The ruthenium complex inspired to the drug NAMI-A, AziRu, prepared (designed and 
developed) by the Department of Chemical Sciences of the University Federico II, Naples 
(Prof. Luigi Paduano, Prof. Daniela Montesarchio). Its pharmacokinetic profile was 
improved by the inclusion in liposomes, which should provide, by a passive targeting, for 
the protection of AziRu and its delivery to cancer cells.   
- The C-N heterocyclic compounds Ruthenium-derived (RDC11) or Osmium-derived 
(ODC2, ODC16, ODC20), prepared (designed and developed) by the Department of 
Chemistry of University of Strasbourg (Prof. Michael Pfeffer).  
Therefore, my research had different focuses: first, the validation of a nanotechnological 
platform of metal-based compounds by evaluation of biocompatibility and cellular uptake 
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of different types of liposomes, as innovative carriers for metal complexes. The second 
point was the analysis of cell death pathways induced by these compounds. Finally, the 
research evaluated the possible targets involved in the mechanism of action. In fact, even if 
these compounds are really largely characterized by biological investigations, their 
mechanism of action, that, as mentioned above, is also closely dependent on redox status 
and chemical ligands, needs further insights. This study was carried out in particular on the 
compounds of RDCs and ODCs families, during the period of my Ph.D. at INSERM 
(French Institute of Health and Medical Research) of Strasbourg (supervisor Dr. Christian 
Gaiddon); in particular, it concerned the evaluation of the epigenetic changes correlated 
with the activity of such compounds and the identification of their specific targets. 
All the results of this work are thus divided, according to the different chemical 
characteristics of the compounds, into four sections: 
- Ruthenium-based nanovectors: comparison between neutral and cationic liposomes 
- DOTAP-TothyCholRu: cholesterol improves the cellular uptake 
- de-LOS-POPC-TothyRu: an alternative liposome inspired to the bacterial wall 
- RDCs and ODCs: the role of epigenetic changes in their mechanism of action 
 10 
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1.1 Classical and epigenetic mechanisms involved in chemotherapy  
Since its multifactorial nature, cancer is nowadays one of the most difficult pathologies to 
eradicate, despite the well validated therapeutic protocols, and the continuous emerging of 
new approaches. There is a wide range of different agents used in chemotherapy that, 
targeting DNA or protein components are aimed to block the DNA replication and, by the 
involvement of several pathways, lead to cell death. In this complex scenario, an important 
role of epigenetic processes has recently emerged, both in the process of carcinogenesis 
and in the mechanism of the anticancer drugs.  
 
1.1.1. Cancer: statistical data and the most used therapeutic approaches  
The term “cancer” indicates a complex scenario of pathological changes characterized by 
deregulation of cell cycle and metabolism, resulting in uncontrolled cell proliferation 
[Teicher et al., 2012]. Since it is a multifactorial disease in which genetic, environmental, 
and lifestyle factors have all together an important impact on the carcinogenesis, cancer is 
at the moment one of the pathologies with larger incidence. The last statistical data about 
the incidence of cancer worldwide are reported by the International Agency for Research 
on Cancer (IARC), the specialized cancer agency of the World Health Organization, and 
are related to 2012 (Fig. 1). An estimated 14.1 million new cancer cases and 8.2 million 
cancer-related deaths happened in 2012, compared with 12.7 million and 7.6 million, 
respectively, in 2008. The most frequent cancers were those of the lung (1.8 million, 
13.0% of the total), breast (1.7 million, 11.9%), and colorectum (1.4 million, 9.7%). The 
most common causes of cancer-related death were cancers of the lung (1.6 million, 19.4% 
of the total), liver (0.8 million, 9.1%), and stomach (0.7 million, 8.8%). Based on these 
estimations it can predict a substantial increase to 19.3 million new cancer cases per year 
by 2025, due to growth and aging of the population [Ferlay J. et al., 2015]. Thus the data 
about the incidence of the cancer join also with a high incidence of death, although the 
research is focused on the identification of new approaches for the cancer therapy, and 
many protocols, based on different method, such as surgery, radiotherapy and 
chemotherapy, are already validated. More recently, the immunotherapy, which comprises 
a wide range of different agents, as immuno-modulatory drugs, vaccines, antibodies 
[Kocoglu and Badros, 2016] is entered in these protocols. The surgical removal of the 
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tumor is the oldest and most effective strategy, but requires that the cancer is localized or 
has limited loco-regional diffusion. Also, the radiation therapy is more efficient if the 
tumor is not largely diffused. Often it is used in combination with chemotherapy and / or 
surgery. It is based on the induction of cell damage by radiation of protons, electrons or 
neutrons, which, however, is nonspecific and increases the risk of secondary tumor 
[Muralidharan et al., 2015]. Chemotherapy has spread from the second half of the 
twentieth century, when research has led to the creation of a wide range of drugs aimed to 
block the DNA replication, such as: DNA alkylating agents (capable to form a covalent 
bond with the purine or pyrimidine bases of DNA), anti-metabolites (like folic acid 
analogs, pyrimidine and purine analogs), the antimitotic agents, topoisomerase inhibitors, 
anti-tumor antibiotics, hormones. Chemotherapy is also the only possible approach for the 
treatment of metastases, which often develop before the tumor is diagnosed. However, 
chemotherapeutic agents have often some limitations, such as poor selectivity, several side 
effects, and onset of resistance mechanisms. 
 
 
Fig. 1. Cancer incidence in the worldwide (2012); indicator: age-standardized rate per 
100,000 (ASR) 
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1.1.2 Types of cell death induced by anticancer agents  
Despite various cellular targets of chemotherapeutic agents, involving metabolic and 
genetic processes, the possible kinds of cell death to which the cancer cells undergo during 
the treatment are few, but however are very important to evaluate the cellular response to 
the drugs. The principal types of cell death are apoptosis, autophagy, necrosis, mitotic 
catastrophe and senescence (Fig. 2). Two of these, the apoptosis and autophagy, are 
considered programmed cell deaths, because of their strict genetic control [Danial and 
Korsmeyer, 2004; Lum et al., 2005]. Necrosis and mitotic catastrophe are generally 
considered passive responses to massive cellular insult. However, new evidence suggests 
that also these kinds of death undergo a genetic control [Castedo et al., 2004; Zong and 
Thompson, 2006]. Senescence is a process of aging, of which nevertheless the deregulation 
could represent a type of cell death in cancer cells [Robles and Adami, 1998; Schmitt et al., 
2002; te Poele et al., 2002]. In the following paragraphs, an overview of the principal 
mechanism of cell death will be presented, particularly focused on their implications 
during the cancer therapy. 
 
 
Ricci et al., Oncologist. 2006; 11(4): 342–357 
Fig. 2. Chemoterapy-induced cell death 
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1.1.2.a. Apoptosis        
The typical morphological characteristics of apoptosis are cell membrane blebbing, cell 
shrinkage, chromatin condensation and nucleosomal fragmentation. In particular, cell 
shrinkage and pyknosis happen during the early process of apoptosis, while extensive 
plasma membrane blebbing occurs followed by karyorrhexis and separation of cell 
fragments into apoptotic bodies [Elmore, 2007]. Generally, there is no inflammatory 
process associated with the apoptosis, because the apoptotic cells don't release their 
cellular components into interstitial tissue and are rapidly phagocytosed, preventing 
secondary necrosis, as well as the phagocytic cells don't produce anti-inflammatory 
cytokines [Savill and Fadok, 2000; Kurosaka et al., 2003]. In fact, a typical biochemical 
aspect that occurs in the early state of apoptosis is the exposition of the anionic lipid 
phosphatidylserine (PS) on the external surface of cancer cells, as signal of “eat me”, 
important for the ordered and quick elimination of cell bodies by macrophages or other 
near normal cells [Hankins et al., 2015]. The apoptosis is an important process both in 
normal and cancer cells that has to be strictly controlled, for its  potential damage in case 
of inappropriate activation in normal cells, as well as in case of deficient activation during 
the anticancer treatment, that represents an important mechanism of drug resistance [Fulda 
and Debatin, 2004]. Apoptosis in response to anticancer chemotherapy can be initiated as a 
result of the activation of receptors on plasmatic membrane (extrinsic pathway) or at the 
mitochondria (intrinsic pathway) [Fulda and Debatin, 2004] (Fig.3). The intrinsic pathway 
is usually activated in response to intracellular stress signals, such as DNA damage, high 
levels of the reactive oxygen species (ROS) [Ricci and Zong, 2006] and endoplasmic 
reticulum (ER) stress [Farooqi et al., 2015], all events that notoriously can take part in the 
mechanism of action of chemotherapeutic agents. ROS can also directly damage DNA by 
causing cleavage of DNA strands, DNA protein cross-linking, and oxidation of purines 
[Marnett., 2000]. The principal response of the DNA damage is the activation of p53 tumor 
suppressor protein, a transcriptional factor that has a key role in the control of cell cycle 
and apoptosis [Meek, 2015]. The extrinsic pathway is triggered by the binding of an 
extracellular ligand to a receptor on the plasma membrane. In particular, is activated by the 
binding of the members of the tumor necrosis factor (TNF) family with their receptors 
(TNFR) [Ricci and Zong, 2006]. Both pathways activate the proteolytic enzymes named 
caspases, containing a nucleophilic cysteine residue involved in the cleavage of aspartic 
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acid-containing motifs [Thornberry and Lazebnik, 1998]. There are two groups of 
caspases, the initiator caspases (caspase-2, caspase-8, caspase-9, and caspase-10), and the 
effector caspases (caspase-3, caspase-6, and caspase-7). They are expressed as inactive 
precursors (procaspases) that form active oligomers after cleavage events, by a cascade 
mechanism that leads to the cleavage of different substrates in the cytoplasm or nucleus 
and thus to the degradation of organelles and disassembly of cellular architecture. For 
example, proteolysis of several cytoskeletal proteins such as actin or fodrin leads to loss of 
cell shape, whereas degradation of lamin results in nuclear shrinking; the DNA 
fragmentation is mediated by the cleavage of ICAD (Inhibitor of Caspase-Activated 
DNase), with subsequent activation of the inhibitor of the endonuclease CAD (Caspase-
Activated DNase) that cleaves DNA into the characteristic oligomeric fragments [Degterev 
et al., 2003]. Stimulation of the TNFR superfamily such as the cluster of differentiation 95 
CD95 (also known as apoptosis antigen-1 APO-1 and Fas) or TNF-related apoptosis-
inducing ligand (TRAIL) receptors results in activation of the initiator caspase-8 which can 
propagate the apoptotic signals by direct cleavage of downstream effector caspases, such 
as caspase-3 [Walczak and Krammer, 2000]. On the other hand, the stimuli that initiate the 
intrinsec pathway lead to the activation of two pro-apoptotic B-cell lymphoma 2 (BCL2) 
proteins, such as Bax (Bcl-2-associated X protein) and Bak (Bcl-2 homologous antagonist 
killer), that migrate to the mitochondria, where homodimerize to expose cryptic dimer-
dimer binding sites and introduce pores into the surface of the mitochondria [Koff et al., 
2015]. This event results in changes in the inner mitochondrial membrane, with increased 
mitochondrial outer membrane permeabilization (MOMP) and loss of transmembrane 
potential, causing the release of pro-apoptotic proteins into the cytosol
 
[Elmore, 2007], 
including cytochrome c and Smac/DIABLO [Saelens et al., 2004]. Once in the cytosol, 
these apoptogenic proteins trigger the execution of cell death by promoting caspase-9 
activation [Kim et al., 2015] and subsequently caspase cascade, or by acting as caspase-
independent death effectors [Saelens et al., 2004]. Links between the extrinsic and intrinsic 
pathways exist at different steps. For example, after the binding of the death receptors, 
activation of caspase-8 may result in the cleavage of Bid, another Bcl-2 family protein, 
which in turn translocates to mitochondria, releasing cytochrome c and thus initiating a 
mitochondrial amplification loop [Adams and Cory, 2002]. In addition, cleavage of 
caspase-6 downstream of mitochondria may feed back to the receptor pathway by cleaving 
caspase-8 [Cowling and Downward, 2002]. However, the concept that caspases have a 
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central role in the mechanism by which chemotherapy kills cancer cells may not 
universally be valid, and both caspase independent-apoptosis and other modes of cell death 
have to be considered as cellular response to anticancer therapy [Brown and Attardi, 2005].  
 
Palade et al., Asian J Neurosurg. 2013; 8(2):106-11 
Fig. 3. Extrinsic and intrinsic apoptotic cascades  
 
1.1.2.b. Autophagy             
The involvement of autophagy in chemotherapy cancer treatment is very complex. On one 
hand, autophagy has a protective role so that autophagy inhibitors have potential use as 
drugs to overcome anticancer therapy resistance. On the other hand, this process 
participates in cell death and its induction may help to eliminate cancer cells [Notte, 2011]. 
Autophagy is a highly regulated and evolutionarily conserved process that is activated in 
response to metabolic stresses, such as nutrient starvation and hypoxia, differentiation, 
endoplasmic reticulum (ER) stress, oxidative stress, expression of aggregate-prone 
proteins, glucose deprivation, with the results of intracellular degradation of proteins and 
organelles [Shintani and Klionsky, 2004]. During autophagy, a portion of the cytoplasm, 
that can include various proteins and organelles, are encapsulated in vesicles called 
autophagosomes, which fuse with the lysosomes, allowing the degradation of the 
cytoplasmic components by lysosomal hydrolases. In physiological conditions this is an 
adaptive response to the stress that contributes to the normal turnover of cytoplasmic 
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components and to maintain the homeostasis [Ricci and Zong, 2006]. However it can lead 
to cell death, if the stress is persistent or excessive. Excessive autophagy is also shown to 
promote cell death following treatment with specific chemotherapeutic agents, either 
because it directly leads to cell death or by an autophagy-mediated induction of apoptosis 
[Sui et al, 2013]. In the first case, autophagy could degrade large parts of the cytosol and 
organelles, leading to irreversible cellular atrophy with a consequent cellular collapse; in 
fact, the large volume occupied by autophagic vacuoles can be approximately equal to, or 
greater than the volume of normal cytosol [Baehrecke, 2005]. In the second case, 
autophagy develops as primary response to stress stimuli and then triggers apoptotic or 
necrotic cell death [Maiuri et al, 2007]. In addition, since the autophagic catabolic process 
is believed to restore ATP levels [Katayama et al., 2007] it could help the apoptosis that in 
turn requires ATP, i.e. for the activation of caspase-9 [Maiuri et al, 2007]. Even if the 
molecular mechanisms by which autophagy mediates its effects on both normal and cancer 
cells are not yet fully clarified, various signaling pathways have been individuated in the 
upregulation or downregulation of autophagy [Glick et al., 2010; Cecconi and Levine, 
2008]. For example, the phosphatidylinositol 3-kinase/mammalian target of rapamycin 
(PI3K/mTOR) and AMP-activated protein kinase (AMPK) signaling pathways have 
emerged as important regulatory processes of autophagy [Din et al., 2012; Yu et al., 2010]. 
Several of the known tumor-suppressor genes, like p53, and tumor-associated genes (p21, 
Akt) also respectively stimulate or inhibit autophagy [Glick, et al., 2010]. Interacting with 
these pathways, several cross-talks are possible between autophagic and apoptotic 
pathways [Maiuri et al, 2007]. Many anticancer drugs stimulate autophagy by inhibiting 
the PI3K/Akt/mTOR pathway or altering genetic/epigenetic phenotype of cancer cells 
[Ciuffreda et al., 2010; Botrugno et al., 2012; Shubassi, 2012], suggesting a synergic role 
of autophagy and apoptosis in the induction of cell death [Notte A., 2011]. In fact, the role 
of autophagy in cell death has been described on different cancer cell lines for several 
drugs, such as etoposide [Cosse et al., 2010; Lee et al., 2007] doxorubicin [Lambert et al., 
2008], carboplatin [Sun et al., 2009] gemcitabine [Mukubou et al., 2010] paclitaxel [Zou et 
al., 2011; Eum et al., 2011]. Also, the histone deacetylase (HDAC) inhibitors, which 
constitute a new class of potential anticancer agents [Gołąbek et al., 2016] are recently 
involved in the control of DNA damage response (DDR) and autophagy [Sui et al, 2013]. 
These different observations show that autophagy takes part in cell death induction in 
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apoptosis competent cells while it becomes the major death inducing pathway in apoptosis 
deficient cells [Notte, 2011].  
 
1.1.2.c. Necrosis and other types of cell death                     
Even if autophagy and apoptosis are considered the principal mechanism of cancer cell 
death in response to chemotherapy, the involvement of other processes cannot be excluded. 
In fact, crosstalk between apoptosis, autophagy and necrosis have been found 
[Nikoletopoulou et al., 2013]. Also, some evidence indicates that necrosis and apoptosis 
represent morphologic expressions of a shared biochemical network described as the 
“apoptosis-necrosis continuum” [Zeiss, 2003]. The term necrosis collects different kinds of 
cell death due to a massive insult, that leads to common morphological changes, including 
cell swelling and plasma membrane rupture, disorganization of structure of organelles, 
without chromatin condensation [Green and Llambi, 2015]. The loss of cell membrane 
integrity results in the release of the cytoplasmic material outside the cells, drawing the 
attention of chemotactic factors and thus with the recruitment of inflammatory cells 
[Elmore, 2007]. While apoptosis is well defined at the molecular level, necrosis has not a 
specific molecular signature and has been referred as uncontrolled and pathological form 
of cell death. Necrosis can be induced by inhibition of cellular energy production, 
imbalance of intracellular calcium flux, generation of ROS, and activation of non-apoptotic 
proteases. These events often potentiate each other and synergize to cause necrosis [Ricci 
and Zong, 2006]. In fact, excessive production of ROS is cause of oxidative stress, DNA 
damage, protein oxidation and lipid peroxidation. Lipid oxidation can lead to the loss of 
integrity of both the plasma membrane and intracellular membranes of organelles, that may 
lead to the influx of Ca
2+
, event that in turn induces cell death by the activation of Ca
2+
-
dependent proteases and mitochondrial Ca
2+
 overload [Waring, 2005]. Recent discoveries 
revealed that also regulated forms of necrosis exist, as in the case of necroptosis [Dunai et 
al., 2011], a programmed cell death fashion, in which specific signaling pathways have 
been individuated and the loss of caspases involvement represents the main difference 
respect to the classical apoptosis [Christofferson and Yuan, 2010]. Several anticancer 
compounds have been reported to initiate necroptosis in cancer cells [Fulda, 2014].  
In the contest of cell death induced by chemotherapy, also mitotic catastrophe and 
senescence are noteworthy. Mitotic catastrophe is referred to the activation of cell death 
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directly from mitosis. Morphologically, mitotic catastrophe is associated with the 
formation of giant cells with either many micronuclei [Ricci and Zong, 2006]. Instead, the 
senescent cells appear large in size, flattened and often vacuolated. The senescence is 
normally considered a process of aging, due to the physiologic erosion of the telomeric 
sequence after a high number of cellular divisions, with subsequent DNA damage. DNA 
damage response could be triggered by other cellular stresses, i.e. some chemotherapeutic 
agents induce a premature senescence [Schmitt et al., 2002; te Poele et al., 2002]. 
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1.1.3 The role of epigenetics in tumorigenesis and in cancer therapy  
The term epigenetic was for the first time coined in the 1942 by Waddington [Waddington, 
2012] as a link between the genotype and the phenotype development. From the mid-
seventies, epigenetics became a real branch of science whose molecular bases are well 
understood. The epigenetic field is constantly evolving, according to the growing 
understanding of DNA methylation, chromatin modifications, and noncoding RNA 
processes, as well as of their effects on gene expression [Choudhuri, 2011]. At the 
molecular level, cancerous phenotype is the result of an altered network of transcriptional 
and post-translational events, regulatory interactions of histone and non-histone proteins 
and chromatin remodeling, in response to dynamic and persistent upstream signals 
[Kumar, 2016]. Thus, in the light of the recent evidences about the role of epigenetic 
factors in carcinogenesis and tumor growth, many researches are pointing to the 
development of new anticancer agents whose targets are chromatin-modifying enzymes 
and proteins involving in the epigenetic processes, as well as to revise the role of 
epigenetics in the mechanism of action of drugs already in use [Davey GE and CA, 2008]. 
 
1.1.3.1. Epigenetic mechanisms 
Modifications of DNA, non-coding RNA and histones are considered the principal 
mechanisms involved in the epigenetic regulation. The most common DNA modification is 
the methylation, especially in a specific region rich in cytosine-guanine bases (CpG 
islands) [Bird, 2002]. This is considered gene repressive, preventing the transcription 
process [De Smet et al., 1999] and it is implicated both in physiological cellular functions 
and in several pathological conditions, among which different kinds of cancer [Shinjo and 
Kondo, 2015]. The modifications of non-coding RNA (ncRNAs) can include the ribosomal 
RNA (rRNAs), micro RNA (miRNAs) and long non-coding sequences (IncRNAs). 
miRNAs play a central role in repression of mRNA stability and translation, de-
adenylation and also regulation by the recruitment of specific proteins to the nucleus 
[Mikhed et al., 2015]. IncRNAs is a family of molecules with different functions, involved 
for example in the cell differentiation and stability of chromosome [Bartel, 2004]. 
Epigenetic modifications observed on histones are methylation, acetylation, ubiquitination, 
sumoylation, ADP-ribosylation [Kouzarides, 2007] phosphorylation and citrullination 
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[Tessarz and Kouzarides, 2014]; each of these has a specific impact on the chromatin 
condensation and on activating or silencing transcription signals [Mikkelsen et al., 2007]. 
Moreover, recently many studies have correlated the redox signaling and the oxidative 
stress with the epigenetic regulation of genes by changes in function of histones and DNA 
modifying enzymes, and thus altering the phenotype of the cells [Mikhed et al. 2015].  
 
1.1.3.2. Histone modifications 
Among the class of molecules epigenetically regulated, there are the chromatin-forming 
proteins namely histones. If before only a "static" action of histones in the DNA packaging 
was known, increasingly discoveries have led to new insights into their role, as a 
"dynamic" system capable of influencing biological cellular processes, like the 
transcription. In performing such function, histone post-translational modifications are 
essential to change the chromatin condensation state and thus the DNA accessibility 
[Falahi et al., 2014]. Since the inhibition of transcription is one of the principal 
mechanisms of action to obtain an antiproliferative effect, histones and the histone-
modifying enzymes, represent nowadays one of the most protein machinery studied as 
possible target for the cancer therapy. 
 
1.1.3.2.a. The chromatin-forming proteins: the histones    
The histones are basic proteins that interact with the DNA by non-covalent interactions, 
allowing its packaging [Felsenfeld, 1978]. In particular, they form an octamer, composed 
by two H2A-H2B dimers and one H3-H4 tetramer, around which 146 bp of supercoiled 
DNA is wrapped in 1,67 turns, to form the nucleosome core particle (NCP) [Luger et al., 
1997; Andrews and Luger, 2011] (Fig.4). The linker histone H1 (or H5, in some case 
[Chen et al., 2014]) completes the DNA compaction, binding to the species-dependent 
fragments of DNA of about 50 bp, close to the entry and exit points of the NCP; together, 
H1 linker and NCP, form the nucleosome, the repetitive unit of chromatin [White et al., 
2016]. Histone H1 is the poorly conserved during the evolution [Kasinsky et al., 2001] and 
has a different structure consisting of a short amino-terminal tail, a central winged-helix 
and a carboxy-terminal intrinsically disordered domain [Roque et al., 2009]. Conversely, 
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the core histones is highly conserved in the evolution [Postberg et al., 2010; Slesarev et al., 
1998], and share a common structural motif, termed "histone fold", consisting of three α-
helices (α 1, α 2, α 3) separated by not structured loops (L1-L2) [Arents et al., 1991]. The 
interactions that stabilize the dimers are mainly of hydrophobic nature, and elapse over the 
entire region of the histone fold. Moreover, two H3-H4 further associate to form a 
tetramer, which has an important role at the beginning of the nucleosome assembly, 
whereas the H2A-H2B doesn't form tetramer. Also, thermodynamic study on H2A-H2B 
showed that the histones are stable only when they are in dimers [Chen et al., 2014]. The 
histone fold domain is joined to two tail regions which protrude from the nucleosome 
[Arents et al., 1995]. These tail regions undergo post-translational covalent modifications 
which are of crucial importance for nucleosome stability [Cascone et al., 2012]. 
 
 
Luger et al., Nature. 1997; 389(6648):251-60 
Fig. 4. X-ray crystal structure of nucleosome core particle of chromatin: phosphodiester 
backbones of 146-bp DNA (brown and turquoise) and histone octamer (blue: H3; green: 
H4; yellow: H2A; red: H2B).  
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1.1.3.2.b. Histone post-translational modifications 
Chromatin has two forms, named euchromatin and heterochromatin. Heterochromatin is 
the most packed form, usually close to the transcriptionally inactive region, while 
euchromatin is the more relaxed form, typically located in transcriptional initiation regions, 
such as promoter and enhancer elements of the gene [Chen et al., 2014]. These two 
different forms can be switched by means of epigenetic modifications on histones, which 
lead to gene repression or activation [Jiang and Pugh, 2009] (Fig. 5). Modifications may 
impact the chromatin state by changing the contact between different histones in adjacent 
nucleosomes or the interaction of histones with DNA, and, depending on the type of such 
modifications, enzymatic proteins, that can further modify chromatin, are facilitated to 
bind chromatin, or are occluded from it. Epigenetic modifications observed on histones are 
methylation, acetylation, ubiquitination, sumoylation, ADP-ribosylation, deimination, 
proline isomerization [Kouzarides, 2007] phosphorylation and citrullination [Tessarz and 
Kouzarides, 2014], that often act in combination, being subjected to cross-regulations 
[Latham and Dent, 2007]. They are prevalently introduced on lysine or arginine residues of 
the N-terminal tails, because of their accessibility [Mikhed et al., 2015]. Histones can 
undergo different kinds of modifications in several times or the same modification at 
different residues. All possible combination patterns of histone modifications give reason 
to coin the expression "histone code" [Jenuwein and Allis, 2001], as an extended pool of 
information to add to the genetic code, in order to better understand the transcription 
process. One of the most known modifications is the acetylation, that has a strong potential 
to unfold the chromatin, since it neutralizes the positive charge of basic aminoacids 
[Saikusa et al., 2015], reducing the interaction between the positive-charged histones and 
the negative-charged DNA. In fact, acetylation is correlated with the formation of the 
euchromatin, and thus making the DNA more accessible to the gene transcription [Dekker, 
2009]. Conversely, histone deacetylation causes chromatin condensation and inhibition of 
transcription [Marks et al., 2001; Gallinari, 2007]. In this context, the enzymes of the 
family histone deacetylases (HDACs) and histone acetyltransferases (HATs) play a central 
role. In fact, many HDACs are over-expressed in malignant cells and they have been 
closely correlated with acquisition of malignant phenotypes in cancerogenesis. In 
particular, depending on the classes of HDACs, they can inhibit apoptosis and induce 
angiogenesis in cancer cells, induce cell proliferation, inhibit differentiation and cause also 
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cell motility, leading to metastasis [Yoon and Eom, 2016]. Moreover, a specific group of 
HDAC, named sirtuins, has a crucial role in the redox signaling, since they are, unlike the 
other classes, NAD
+
- rather than Zn-dependent enzymes [Webster et al., 2012]. For all 
these observations, HDAC inhibitors are nowadays object of studies for making targeted 
anticancer agents, many of which are in clinical trials [Xu et al., 2007], and some are 
already approved [Gryder et al., 2012]. 
 
Falahi et al., Breast Cancer Research 2014; 16:412 
Fig. 5. The two forms of chromatin (active euchromatin and repressed heterochromatin) 
and their interaction with epigenetic players, classified in enzymes that induce  
modifications (writers) or removing them (erasers) or factors that bind these modifications 
(readers) and recruit further re-enforcing complexes. The role of DNA methyltransferases 
(DNMTs) and their inhibitors (DNMTis), as well as histone acetyltransferases (HATs), 
histone deacetylases (HDACs) and their inhibitors (HDACis) is highlighted.  
 
1.1.3.2.c. Histones localization 
Beside the well known nuclear functions, recently new roles of the histones in extra-
nuclear compartments have emerged. In fact, histones can be released by stressed cells in 
intracellular space, where they can act as endogenous danger signals in different 
pathological conditions [Chen et al., 2014] (Fig. 6). Histones release by neutrophils in the 
context of neutrophil-mediated cell death was the first reported example in literature 
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[Brinkmann et al., 2004]. Also apoptotic or necrotic cells can release extracellular histones 
[Jahr et al., 2001]; generally, nuclear components are not released during apoptosis, but 
increasing evidence indicates that cells undergoing apoptosis possess this ability. In 
particular, in response to apoptotic signals, core and linker histones can separate from 
DNA, with subsequent histone cytoplasmic translocation and then their release into the 
extracellular space, phenomena that are not necessarily connected to the apoptotic DNA 
fragmentation [Wu et al., 2002]. Moreover, the chromatin damage could be an early cause 
of histones release preceding the apoptosis [Gabler et al., 2003], and lead to an 
accumulation of cytoplasmic histones inducing the intrinsic pathways of apoptosis by 
destabilization of the mitochondrial membranes [Cascone et al., 2012]. Also, extracellular 
histones can in turn act as apoptotic signals for the neighboring cells, by means of different 
mechanisms, including induction of calcium influx, enhancement of the endoplasmic 
reticulum unfolded protein response, and increase of mitochondrial toxicity [Chen et al., 
2014]. Nevertheless, the specific extracellular signaling capable of inducing apoptosis by 
histones release has yet to be clarified.  
 
Chen et al., Cell Death Dis. 2014; 5:e1370 
Fig. 6. Scheme of all the possible signaling pathways induced by extranuclear histones in 
different pathological conditions  
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1.2. Anticancer metal-based drugs 
The anticancer metal-based drugs constitute nowadays an important and heterogeneous 
class of compounds, of which the common thread is the presence of an inorganic active 
principle. The classical platinum-based agents are an important class of chemotherapeutics, 
and several studies are still focused on giving a complete view of their mechanism of 
action, as well as on making modification of their structure, in order to ensure the 
pharmacokinetics and pharmacodynamics. On the other hand, a series of new transition 
metal-based compounds, such as ruthenium and osmium-based, are object of numerous 
studies for their more attractive cytotoxic profile, including a high antiproliferative activity 
associated with less side effects. 
 
1.2.1. Cisplatin and its analogs 
Even if they don't have an alkyl group, the platinum compounds are classified in the class 
of alkylating agents, for their capacity to intercalate the DNA. The potential anticancer 
activity of platinum was serendipitously discovered, by Rosenberg and co-workers 
[Rosenberg et al., 1969]. During an experiment aimed to understand the effects of electric 
field on the growth of Escherichia coli bacteria, they observed that the passage of current 
between two platinum electrodes prevented the proliferation of E. coli. The 
antiproliferative effect was attributed to the formation of platinum-containing compounds 
in the presence of inorganic ammonium ions and chlorine. Rosenberg hypothesized that if 
these complexes inhibited bacterial cell division, they could also stop tumor cell growth. 
The more active among these substances in experimental models of tumor was the 
diamminodichloro cis-platinum (II) Cis- [PtCl2 (NH3) 2] (Fig.7). Indeed, in 1978, six 
years after clinical trials conducted by the NCI and Bristol-Myers-Squibb, the U.S. Food 
and Drug Administration (FDA) approved cisplatin for treating patients with metastatic 
testicular or ovarian cancer in combination with other drugs and also alone for treating 
bladder cancer [Monneret, 2011]. The first mode of action proposed for these compounds, 
that represent still the principal mechanism recognized for their action, is the DNA 
binding. When cisplatin enters the cell is hydrolyzed, forming a positively charged 
molecule that reacts with nucleophilic groups present on the DNA. In particular it binds the 
N-7 of the guanine [Bernges and Holler, 1991] forming intra and inter-strand crosslinks 
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[van den Berg and Roberts, 1975], that is the cause of DNA distortion, inhibition of DNA 
replication and transcription. On the other hand, the DNA damage causes the activation of 
transduction pathways, involving the Ataxia telangiectasia mutated and Rad3-related 
(ATR) protein kinase, p53 and p73 proteins, and the mitogen-activated protein 
kinases (MAPK), leading to the apoptosis [Siddik, 2003]. Bristol-Myers Squibb also 
licensed carboplatin, a second-generation platinum drug with fewer side effects [Sharma et 
al., 2011]. Carboplatin is formed by replacing the chloride with 1,1-
cyclobutanedicarboxylate ligand, which increases the stability of the leaving groups 
[Muggia et al., 2015]. Numerous platinum derivatives have been further developed and the 
third derivative to be approved in 1994 was oxaliplatin. Respect to cisplatin, the two amine 
groups are replaced by cyclohexyldiamine to improve antitumor activity [Ramachandran et 
al., 2009], while the chlorine ligands are replaced by the oxalate-bidentate derived from 
oxalic acid in order to improve water solubility. Differently from cisplatin and carboplatin, 
oxaliplatin in plasma rapidly undergoes non-enzymatic transformation into reactive 
compounds because of displacement of the oxalate group. Most of these formed 
compounds appear to be pharmacologically inactive, but dichloro-platinum complexes 
enter the cell, where carry out their mechanism of action [Alcindor and Beauger, 2011]. 
Oxaliplatin was the first platinum-based drug to be active against metastatic colorectal 
cancer in combination with fluorouracil and folinic acid [Monneret, 2011]. 
 
 
Fig. 7. Cisplatin and its derivatives 
 
Nevertheless, platinum compounds are mutagenic, teratogenic and show a high toxic 
profile (i.e. nausea and vomiting, diarrhea, myelosuppression, neuropathy, ototoxicity, 
hepatotoxicity and nephrotoxicity) [Apps et al., 2015]. Moreover, among the long-term 
effects of cisplatin treatment, has been mentioned an increased risk of development acute 
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myeloid leukemia (AML) [Philpott et al., 1996]. Also, the cancer cells have demonstrated 
resistance phenomena to cisplatin and its analogs. The principal platinum resistance 
mechanisms are: reduced cellular uptake and up-regulated drug efflux from cells, increased 
degradation and detoxification of the drugs by glutathione (GSH) activity, reduced 
formation of drug-DNA adducts and an increased tolerance or repair of the damaged DNA 
[Galluzzi et al. 2012]. 
 
1.2.2. New transition metals-based complexes 
Metal complexes, in particular transition-metal-based complexes, have potential 
advantages respect to the organic-based drugs, including the possibility to occupy a high 
number of spatial positions due to their octahedral coordination geometry, the possibility 
of functionalization with different ligands that could change the thermodynamic and 
kinetic characteristics, and an important role of the oxidation/reduction state that allows 
them to be present in the biological fluids [Clarke et al., 1999]. The current platinum drugs, 
that are nowadays still one of the most used classes of chemotherapeutics, have some 
limitations: they are efficient only for a limited range of cancers and often cause severe 
side effects; in addition, some tumors showed acquired or intrinsic resistance [Köberle et 
al., 2010]. Although other platinum compounds are in clinical trials, they have not been 
able to overcome the drawbacks associated with cisplatin [van Rijt and Sadler, 2009]. Thus 
the research focused on the individuation of other transition metals, which have a similar 
chemical profile to platinum, but with fewer side effects. The ruthenium compounds are 
considered suitable candidates for anticancer drug design, because they have a similar 
spectrum of ligand substitution kinetics as platinum (II). After the pioneer works of Clarke 
[Clarke et al., 1980], Sava and co-workers were the first designers of one of the most 
promising complexes of low molecular weight based on ruthenium (III), called NAMI-A 
[Sava et al., 1998]. Subsequently, the same group has also tested the compound KP1019, 
made by Keppler and co-workers [Kersten et al., 1998; Bergamo et al., 2009]. These 
compounds have entered in the clinical trials in the 1999 and 2003 respectively [Galanski 
et al., 2003]. NAMI-A, now in the phase II of clinical trials [Bergamo and Sava, 2015], has 
been proposed for the combination therapy with gemcitabine as a second line therapy for 
the metastatic non-small cells lung cancer (NSCLC) [Leijen et al., 2015]. Despite the 
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structural similarities to NAMI-A, the compound KP1019 (Fig. 8) showed different 
pharmacological profiles.  
 
Fig. 8. Molecular structure of NAMI-A and KP1019 
 
While KP1019 have a high cytotoxic effect on primary tumors [Kapitza et al, 2005], 
NAMI-A seems prevalently to be able to reduce metastases from solid tumors [Sava and 
Bergamo, 2000; Sava et al., 2003]. Also, NAMI-A is less toxic respect to cisplatin. An 
hypothesis for this difference lies in the diverse capacity to bind serum proteins. In fact, 
even if they bind approximately the same serum proteins, the NAMI-A binding is more 
reversible [Khalaila et al., 2006]. Differences between NAMI-A and cisplatin have been 
showed also for the mechanism of action. In fact, even if a binding to DNA by NAMI-A 
was found, this is weaker than that of platinum complexes [Pluim et al., 2004.], excluding 
thus the role of DNA as the primary target for its activity on metastases. Its antimetastatic 
activity seems due to an intricate network of actions, including the transforming growth 
factor beta 1 (TGF-β1)-dependent fibrosis induction, the reduction of the release of the 
matrix metalloproteinases (MMPs) in the primary tumour and the extracellular matrix 
(ECM) remodeling, probably because it interacts more with targets outside the cells (like 
α5β1 integrin) than inside the cells [Brescacin et al., 2015; Pelillo et al., 2015]. In the case 
of KP1019, the induction of apoptosis via the mitochondrial pathway, also generating ROS 
species, was found [Hartinger et al., 2006]. A confirmation of the involvement of ROS is 
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given by the suppression of the cytotoxicity of KP1019 by the pre-treatment of cells with 
the antioxidant N-acetylcysteine [Kapitza et al., 2005]. Although the mitochondrial 
pathway is considered responsible at least for its in vitro effect, a role of DNA binding is 
not excluded, as shown by the studies with DNA repair inhibitors [Hartinger et al., 2006]. 
Despite the differences observed in their activity, some aspects of this first generation of 
ruthenium compounds are believed in common: 
i) The hypothesis of activation by reduction: ruthenium can be in the oxidation states 
of Ru (II), Ru (III) and Ru (IV) under physiological conditions. It is believed that 
Ruthenium (III) and Ru (IV) are less active and act as a pro-drug converted in the 
active form Ru (II) prevalently in the redox microenvironment of cancer cells 
[Clarke et al., 1999], as well as by the higher levels of  glutathione present in these 
cells [Allardyce and Dyson, 2001] (Fig.9). 
 
ii) Transport by transferrin: serum proteins as albumin, transferrin and globulins are 
believed to play a crucial role in the transport, delivery, and storage of anticancer 
metallodrugs. In particular, ruthenium complexes demonstrated high affinity for the 
protein transferrin [Groessl et al., 2010; Brabec and Nováková, 2006] the main 
transport protein of iron, whose request increases in tumor and metastatic cells 
[Corcé et al., 2016]. In fact, due to their intensive proliferation, tumor cells require 
large quantities of nutrients, particularly iron, that has a central role in numerous 
biological processes, and it is an essential part of many proteins and enzymes, such 
as the ribonucleotide reductase, responsible for the conversion of ribonucleotides 
into deoxyribonucleotides for the DNA synthesis [Lammers and Follmann, 1983].  
 
iii) DNA binding: although the pharmacological targets for ruthenium compounds have 
not been unequivocally identified, the cytotoxicity of many of these complexes 
correlates with their ability to bind DNA. Several ruthenium compounds bind DNA 
and modify it differently than cisplatin or its analogues [Brabec and Nováková, 
2006]. However NAMI-A and KP1019 showed a low profile of interactions, that is 
not enough to explain the wide range of their effects [Pluim et al., 2004; Bergamo 
et al., 2012]. 
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Allardyce and Dyson, Platinum Metals Rev. 2001; 45(2): 62-69 
 
Fig.9. Different ruthenium activities in cancer and healthy cells due to the transferrin 
transport and the "activation by reduction" in cancer cell enviroment.  
Nevertheless, these assumptions are currently only hypotheses, that, as well discussed 
recently by Bergamo and Sava [Bergamo and Sava, 2011], need further investigations to 
be validated. After the promising results on NAMI-A and its analogs, many works have 
focused on the identification of other kinds of ruthenium-based compounds, playing to 
modify the structure-relationship. In particular, these compounds can be divided into two 
general classes: the ruthenium arene complexes and the bifunctional complexes with 
polypyridyl and arylazopyridine ligands (Fig. 10). The half-sandwich Ru (II) arene 
complexes in which ruthenium is bound to an aryl group, two ligands YZ such as two 
amino groups, and a good leaving group X, such as chlorine, offer great scope for the 
design, with the potential to vary each of the building blocks, allowing modifications of 
thermodynamic and kinetic parameters [van Rijt et al., 2009]. Also, the arene has a crucial 
role in the mechanism of action because it works as a DNA intercalator [Liu et al, 2006]. 
The RAPTA family (Ru[η6-arene][PTA]X2], PTA = 1,3,5-triaza-7-phosphaadamantane) is 
an evolution of this class, and includes promising compounds [Murray et al., 2016; 
Nowak-Sliwinska et al., 2011]. Among these, the complex RAPTA-C showed stronger and 
more selective affinity to protein targets than platinum compounds [Casini et al., 2009]. 
Recently, RAPTA compounds were also conjugated with polymeric micelles to improve 
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the drug delìvery [Lu et al., 2015; Blunden et al., 2013]. In addition, the class of the 
bifunctional complexes with polypyridyl and arylazopyridine ligands show promising 
cytotoxic activity that is structurally-dependent [Besker et al., 2007; van Rijt and Sadler, 
2009]. It was proved that the cytotoxicity of some of these compounds depends on the 
activation of mitochondria-mediated apoptosis pathway [Chen et al., 2010]. 
 
van Rijt et al., Drug Discov Today. 2009; 19(10):1640-8  
Fig. 10. [A] Sandwich model for metal-based drugs; [B] Azopyridine ruthenium-based 
Although osmium has a reputation for its toxicity (OsO4), the anticancer potential of this 
metal has recently been explored. In fact, some complexes inspired to the structure of the 
ruthenium compounds, as azole complexes [Kuhn et al., 2014], arene complexes [Peacock 
and Sadler 2008; van Rijt et al., 2009], and RAPTA analogs [Hanif et al., 2014] were 
designed and developed. Osmium complexes have different kinetics and thermodynamics 
of the reaction respect to the ruthenium compounds and showed more stability in aqueous 
solution [Hanif et al., 2014]. Also, they don't give cross-resistance with cisplatin towards 
cancer cells, suggesting a possibility to overcome the problem of intrinsic or acquired 
resistance in chemotherapy [Peacock and Sadler, 2008]. As for the ruthenium compounds, 
the DNA binding is not considered the principal mechanism of action; conversely, there 
are many evidences about their redox activity and apoptosis activation mediated by ROS 
production [Maillet et al., 2014; [Hanif et al., 2014; Hearn et al., 2012]. At this point it's 
clear that the comprehension of the mechanism of action of the transition metal-based 
compounds, and more in general of their pharmacodynamics, must take account of the 
complex structure-activity relationships, the different kinetics of ligand substitution 
reactions, as well as the different metal redox potential. Therefore, each compound can 
have a specific pool of interactions with various proteins/enzymes, playing a crucial role in 
inducing the observed variegate biological effects [Casini, 2012].  
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1.3. Nanovectors as innovative pharmaceutical forms for drug delivery 
Classical cancer chemotherapy showed several drawbacks, such as adverse 
pharmacokinetic profiles, poor aqueous solubility, low therapeutic index, rapid clearance, 
instability, various collateral effects, and emergence of multidrug resistance (MDR) 
phenotypes [Chidambaram et al., 2011]. For this reason the research is focusing not only 
on the individuation of new active principles, but also on the discovery of new systems for 
drug delivery. In this contest, the application of the nanotechnologies on the medicine field 
seems to be very successful. In the following paragraphs, the principal supramolecular 
assemblies used in nanochemotherapy, as well as some of the most suitable materials for 
their realization, are described. 
 
1.3.1. Liposomes and micelles 
As reported by the U.S. National Institute of Health (NIH), nanotechnology will 
completely change the scenario of cancer diagnosis, treatment, and prevention 
[http://nano.cancer.gov] because of the easiness to modulate the physical parameters of the 
nanoparticles, like size, shape and surface physiochemical propriety, making them suitable 
for many applications. For these reasons nanovectors result very versatile, allowing for 
example the drug delivery by mechanism of passive or active targeting, the improvement 
of the drug passage through biological barriers, the protection of the active principle in the 
blood and thus also the reduction of the drug cytotoxicity [Jhaveri and Torchilin, 2016]. 
The main forms of nanovectors are dendrimers, vesicles, micelles, core-shell particles, 
microbubbles, and carbon nanotubes [Janib et al., 2010]. In particular, there is a growing 
interest for lipid-based nanoformulations, for the advantages related to the high degree of 
biocompatibility [Matougui et al., 2016]. Among the lipids used for this purpose, there is 
the zwitterionic POPC (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) [Stano et al., 
2004], a very stable lipid synthetically provided (Fig. 11). The fatty acid composition, i.e. 
saturated chain in the sn-1 position and unsaturated chain in the sn-2 position, mimics 
mammalian phospholipid composition. Since the major constituent in eukaryotic cell 
membranes is 1-palmitoyl-2-oleoyl PC, POPC is an excellent synthetic substitute. 
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Fig. 11. Molecular structure of POPC 
The ionic lipid DOTAP (N- [1- (2,3-dioleoilossi) propyl] -N, N, N-trimethylammonium 
methyl-sulfate) contains two chains of oleic acid linked with a propyl-amine [Marsh, 2012] 
(Fig. 12). This synthetic lipid has been recently studied  to make cationic aggregates, that 
should better interact with the cell membranes, negatively charged because of the presence 
of anionic sugar residues of glycoproteins and glycolipids. [Stebelska et al., 2006 ]. 
 
Fig. 12. Molecular structure of DOTAP 
 
The main formulations that lipids are able to form spontaneously are micelles and 
liposomes. 
 Micelles: the amphiphilic molecules consist of a single acyl chain forming a 
conical shape. At concentration values equal to the Critical Micelle Concentration 
(CMC) [Toh HS and Compton RG, 2015; Corrin et al., 1947] they can aggregate in 
micelles with the polar heads towards the outside and the hydrophobic tails towards 
the interior, without forming a double layer (Fig. 13). Consequently, the micelles 
have a lipophilic core. 
 
 Liposomal vesicles: phospholipids or surfactant molecules containing two acyl 
chains, which have cylindrical geometry, ordering in planar sheet, forming a double 
layer (bilayer) which shapes a spherical structure, thermodynamically favored, with 
a central aqueous compartment [Monteiro et al., 2014] (Fig. 13).  
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Toh and Compton, Chem Sci.  2015; 6:5053-5058 
 
Fig. 13. Simplified model of aggregation in micelle (on left) and the liposome (on right) 
Liposomes were initially designed by the biophysicist Bangham as simplified models of 
cell membranes [Bangham  et al., 1965] and only later it was evaluated the possibility of 
using them as vectors in diagnostics, immuno-modulation, genetic engineering and 
chemotherapy [Gregoriadis et al., 1974]. Therefore, the liposomes can incorporate both 
hydrophilic (in the aqueous core), and lipophilic drugs (between the alkyl chains). 
Moreover, they can be divided according to their size and number of lamellae [Monteiro et 
al., 2014] (Fig. 14):  
 - MLVs, multilamellar vesicles (0.1–15 µm). These vesicles are formed by more bilayers, 
which can incorporate high amounts of lipophilic drugs, but they are easily recognized by 
the reticulo-endothelial system. The presence of more lamellae can also be exploited for a 
prolonged drug release. 
- MVVs, multi-vesicular vesicles (1.6–10.5 µm). Complex systems of vesicles that contain 
inside more vesicles. 
- LUVs, large unilamellar vesicles (100 nm to 1 µm), constituted by a single lamella.  They 
are useful for incorporating macromolecules and hydrophilic drugs, but are easily 
recognized by the reticulo-endothelial system. 
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- SUV, small unilamellar vesicles (25–50 nm), constituted by a single bilayer. They have 
very long half-life because of their small size and thus are not recognized by the reticulo-
endothelial system. 
 
 
Monteiro et al., J R Soc Interface. 2014; 11(101): 20140459 
Fig. 14. Representation of various types of liposomal vesicles 
An important parameter for the liposomes is the lipid phase transition temperature (Tm) 
[Kraft et al., 2014], that is the temperature at which an ordered and rigid lipid membrane 
(gel phase) changes in a more disordered, fluid membrane (sol phase). Tm depends on: the 
kind of lipids (liposomes with saturated fatty acids are better compacted and therefore have 
a high Tm), the temperature of liposomes preparation, the presence of cholesterol. The 
cholesterol, similarly to its function in biological membranes, intercalates between the acyl 
chains, giving a double effect: condensing at a higher Tm (reduces the freedom of 
movement of the chains) or fluidifying at lower Tm (prevents intermolecular bonds 
between lipids). Therefore, by modulating parameters such as the size, composition, charge 
density, membrane fluidity, steric hindrance and permeability, it is possible to influence 
the interaction of the liposome with the tissues and the drug release. It was assumed that 
the liposomes can interact and/or penetrate cells through several mechanisms. In particular, 
some experiments conducted both in vitro and in vivo showed that the main interactions of 
liposomes with cells are simple adsorption (by specific interactions with cell-surface 
components, electrostatic forces, or by non-specific weak hydrophobic forces) or following 
endocytosis [Akbarzadeh et al., 2013]. Liposomal aggregates of nanometer size (between 
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10-1000 nm), represent an efficient therapeutic formulation combining the advantages of 
their shape with the small size and the ability to carry the drug. Thanks to the small size 
and the shape, the delivery of the drug is then favored to the cancer cells which, having 
different characteristics from the other tissue, allow the accumulation of the nanoparticles 
and make possible the "passive targeting" (Fig.15).  
 
Estanqueiro et al., Colloids Surf B Biointerfaces, 2015; 126:631-48 
Fig. 15. Illustration of the nanoparticles passive accumulation in the cancer tissue, due to 
the EPR effect 
This process is called EPR (Enhanced Permeability and Retention) effect [Gill et al., 2015; 
Maruyama, 2011]. The tumor undergoes an angiogenic process by which develops a 
network altered blood, with widely fenestrated capillaries and reduced lymphatic drainage; 
this can lead to accumulation of molecules transported from the bloodstream into the 
interstitial space of the tumor cells [Seymour et al., 1994]. In addition, it is possible an 
"active targeting" by inserting of further components on the surface of nanovector, making 
it selective for a specific type of tumor. For example, the inclusion of hyaluronic acid 
causes a selective interaction with ovarian and colon cancer cells, overexpressing the 
receptor for hyaluronic acid. [Luo et al., 2002]. Also, liposomal formulations can be easily 
designed with ad hoc modifications in order to modulate their pharmacokinetics; for 
example, by adding a chain of polyethylene glycol (PEG), prolongs the half life of the drug 
because, due to its high hydrophilicity, interposes in the external versant of liposomal 
surface, obstructing the binding with other macromolecules and preventing recognition by 
the reticulo-endothelial system and thus the macrophages-dependent phagocytosis 
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[Gabizon et al., 2004]. These "pegylated" liposomes, able to evade the immune system by 
prolonging the half-life of the drug, belong to the second generation of liposomes, called 
"stealth liposomes" [Immordino et al., 2006; Cattel et al., 2003]. For example, 
nanoparticles of polyethylene glycol phosphatidyl ethanol amine (PEG-PE) containing 
doxorubicin have shown an increase of the antiproliferative effect of the drug, in addition 
to a lower cardiotoxicity [Tang et al., 2007]. Liposomal doxorubicin was the first 
nanovector approved by the Food and Drug Administration (FDA) for the Kaposi's 
sarcoma [Presant et al., 1993; Masood et al., 1993]. Currently there are more than 50 
anticancer nanovectors in clinical trials [Wang and Thanou, 2010] among which the SPIO 
(superparamagnetic iron oxide) to diagnose pre-operative stage of pancreatic 
cancer [Flexman et al., 2008] and also lyso-thermosensitive liposomal doxorubicin as a 
novel activated therapy using radiofrequency ablation [Poon and Borys, 2009]. Interesting, 
several systems, i.e. liposome, micelles and dendrimers are studied also as carrier of 
platinum compounds [Oberoi et al., 2013; Parker et al., 2016].  
 
1.3.2 Supramolecular nucleolipids systems are good candidates for drug delivery 
There are numerous natural and synthetic molecules with amphiphilic properties that can 
be used for the preparation of supramolecular aggregates. Among these, the amphiphilic 
nucleolipids obtained considerable interest in recent years [Gissot et al., 2008]. Consisting 
of a purine or pyrimidine nucleoside, these compounds are used as a polyfunctional 
"scaffold", of which the ribose can be functionalized with aliphatic chains of variable 
length. The discovery of these systems started from the study of natural hybrid nucleolipids 
and recognition of their biological relevance. In fact, there are many nucleolipidic 
complexes that in both eukaryotic and prokaryotic cells have important physiological roles. 
Just think of the coenzyme CDP-DAG (diacyl glycerol citidin-phosphate) that plays a 
central role in the metabolism of the membrane lipids phosphoinositides and the 
mitochondrial membrane components cardiolipins [Heacock and Agranoff, 1997]. Based 
on its structure, several synthetic analogues were then obtained, initially with the only 
purpose of blocking the RNA transcription and of using them as anti-cancer drugs or anti-
viral, as false substrates of the RNA polymerase [Gissot et al., 2008]. The inclusion of lipid 
chains improves the cellular uptake (indeed the phospho-ester bond is hydrolyzed directly 
in the cytoplasm, reducing the toxicity) and allows also the aggregation between the polar 
Background 39 
 
heads and the hydrophobic chains. The result is that the formulations, compared to 
classical amphiphilic compounds, have a polar head (adenine, thymine, guanine, uracil or 
similar) capable of forming hydrogen bonds and π-stacking that improve recognition with 
other nucleobases and thus the self-assembly. For these reasons, in the mid 80' these 
complexes were investigated not only for their pharmacological activity, but also for their 
ability to auto-aggregate under suitable conditions, forming vesicles, micelles and 
monolayers, which can act as carriers for the drug delivery [Rubas et al., 1986; 
Schwendener, et al., 1985]. These complexes interact easily with biological membranes 
and thus promote the cellular uptake of the active ingredients, reducing the premature 
release in the bloodstream and also protecting it from enzymatic degradation. Since 2002 
were tested new complexes in which, in place of the functionalization of the position 5 'of 
ribose with fatty acids, the positions 3' and 2' were derivatized, to analyze any changes in 
the physico-chemical characteristics of the complex, as well as its ability to self-assembly. 
Therefore, by modulating the three functionalizable positions, prototypes with different 
ionic characteristics (amphiphilic, anionic, zwitterionic, nonionic) were obtained [Gissot et 
al., 2008] (Fig. 16). 
 
Gissot et al., Org. Biomol. Chem., 2008; 6(8):1324-33 
Fig. 16. Nucleolipidic prototypes with different ionic characters 
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Other promising compounds are the neutral glycosylated derivatives in which the 
interactions for the self-assembly occurs not only between the nitrogenous bases but also 
between the phosphate-sugar groups [Arigon et al., 2005], or the neutral nucleoside 
functionalized with the poly-ethylene glycol [Barthelemy et al., 2005] (Fig. 17). 
 
Gissot et al., Org. Biomol. Chem., 2008, 6(8): 1324–1333  
 
Fig. 17. Nucleolipids in which the position 5' is functionalized with glucose or PEG 
The use of oligonucleotides was tested on the first time for the antisense antiviral therapy 
[Wilson and Keefe, 2006]. Also these complexes, known by the initials ONA 
(oligonucleotide-based amphiphiles), showed ability in auto-aggregation in micelles or 
vesicles [Alemdaroglu and Herrmann, 2007]. Often the oligonucleotides are 
functionalizated with cholesterol; in fact it is recognized by receptors of low-density 
lipoprotein (LDL) facilitating the endocytosis process [Krieg et al., 1993]. 
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2. Ruthenium-based nanovectors:  
      comparison between neutral and 
cationic liposomes
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2.1. INTRODUCTION 
2.1.1. The active principle: AziRu 
AziRu is the low molecular weight ruthenium-based complex (Fig.18) synthesized by Prof. 
Paduano and Prof. Daniela Montesarchio (Federico II University, Naples); this is a NAMI-
A analog in which, instead of the imidazole, there is the pyridine. This substitution gives 
more lipophilicity to the complex that should more easily interact with the cell membrane; 
in fact, under the same conditions, the IC50 relative to AziRu are lower than those 
calculated for NAMI-A [Mangiapia et al., 2012].  
 
 
Fig.18. The low molecular weight complex AziRu 
 
Also, both AziRu and NAMI-A are able to selectively interact with GG-containing DNA 
model systems, but AziRu is sensibly more reactive than NAMI-A [Musumeci et al., 
2015]. Thus, this only change in the structure is responsible for the increase in the 
reactivity of the metal, able to form stable adducts with guanine-containing 
oligonucleotides. Interestingly, AziRu and NAMI-A showed different profiles of reaction 
with model proteins, such as the egg white lysozyme (HEWL). These two Ru-compounds, 
which are structurally very similar, making different adducts with HEWL, with distinct 
metalation sites [Vergara et al., 2013; Messori and Merlino, 2014]. Although the metal 
ligands could be eventually lost in the final products of the reaction, these findings remark 
the importance of them in the interaction of Ru-based drugs with proteins and in the kind 
of the adducts that are formed, thus changing also the pharmacological activity. Moreover, 
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by crystallographic studies, an inhibition of the RNAase A by AziRu was found [Vergara 
et al., 2013], suggesting that other enzymes could be inhibited "in vivo" and that this 
activity may have a central role in the AziRu mechanism of action. However, as the 
NAMI-A, AziRu are not stable over time in physiological solutions at neutral pH 
[Mangiapia et al., 2012]. Also, the IC50 of AziRu is still too high to be considered an 
antiproliferative agent. Considering these aspects, the inclusion in nanocarriers could 
improve its stability. It may represent a good strategy both to evaluate a new platform of 
nanotecnological agents, and to individuate the pharmacodynamics of the ruthenium 
complex, whose the most part could be directly vehiculated inside the cells, by-passing all 
the physio-chemical implications and the pharmacokinetic processes to which these 
compounds are subjected in the blood [Levina et al., 2009]. 
 
2.1.2 ToThy, HoThy, DoHu: amphiphilic nucleolipids for the delivery of AziRu 
Self-assembled amphiphilic aggregates represent nowadays a new strategy for the delivery 
of the anticancer agents. The advantages of these nanostructures are: the capacity to 
delivery in a safety way the active principle in the blood, to be “stealth” to the human 
immune system, increasing thus the life-time of the drug, to be selective toward cancer 
cells by passive or active targeting and the possibility of easily changing the shape and size 
both by directly modulating their molecular structure or external physicochemical 
parameters, like pH and ionic strength [Mangiapia et al., 2004; Vaccaro et al., 2006]. In 
this context, our research group has designed and tested different nanoaggregates, 
belonging to a new bio-technological platform in which the active principle is AziRu 
[Mangiapia et al, 2012; Simeone et al., 2011]. In particular, three different types of 
amphiphilic nucleolipidics are used for the self-assembly, each  one  functionalizated with 
AziRu (Fig.19): Tothy: 3- [4-pyridylmethyl] -30-O-oleoyl-50-O (monomethoxy) 
triethylene glycol-acetyl-thymidine;  HoThy: 3- [4-pyridylmethyl] - 30- O- oleyl 50-O 
(benzyloxy) exaetilen glycol-acetyl-thymidine; DoHu: 3- [4-pyridylmethyl] 20, 30 of O- 
oleil- 50-O- (benzyloxy) esaetilen glycol-acetyl-uridine  
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Fig.19. Amphiphilic nucleolipids ruthenium-based 
 
We can thus describe their structure activity relationships (SARS): 
- The pyrimidine deoxyribo- or ribo-nucleoside (Thymidine, as in the case of ToThyRu 
and HoThyRu; Uridine, for DoHuRu) constitutes the central scaffold on which to place 
different functions. 
- The active principle, AziRu, is bound to the N3 of the methyl-pyridine arm. 
- One (or two groups in the case of DoHu) lipophilic chain attached at the hydroxy  3' (and 
2') of the ribose. It is used to induce the self-assembly in aqueous solutions. The choose of 
the oleic acid as "building block" is due to its commercially available and also for its 
structural similarity with the components of cell membranes. 
- An oligo ethylene-oxide chain at the hydroxy 5' of the ribose not only serves to optimize 
the hydrophilic-lipophilic balance, but also to prevent the extracellular degradation; in fact, 
like the widely used polyethylenglycol (PEG), this hydrophilic chain could have the 
capacity to mask the system in the blood, make it a "stealth liposome" 
Both hydrophilic and lipophilic components are linked to ribose through ester linkages, 
stable in neutral and extracellular media but easily degradable by cellular esterases, thus 
promoting the release of the drug. Previous results [Simeone et al., 2011] showed that 
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ToThy, HoThy, DoHu self-assembled in pure water or under pseudo-physiological 
conditions, as well as in vitro experiments confirmed their biocompatibility, essential 
condition to use these aggregates as inert carriers of the drug. In particular, they were 
analyzed by dynamic light scattering (DLS) to estimate aggregate dimension and small 
angle neutron scattering (SANS) to analyze the aggregate morphology and to determine 
their geometrical characteristics. They showed a strong ability to organize into vesicles, 
whose hydrodynamic radius is between 50 and 400 nm. In pure water they can also be 
organized in cylindrical micelles; it should be noted that the vesicles are preferable because 
they have a larger and more stable architecture when their size is maintained in a range 
from 50 to 100 nm. The in vitro bioscreening conducted on a panel of cell lines, including 
murine fibroblasts (3T3-L1), human neuroblastoma cells (SH-SY5Y), rat glioma cells 
(C6), human cervical cells (HeLa), and human colorectal adenocarcinoma cells (Caco-2), 
demonstrated that the nucleolipids can be used as biocompatible vectors, showing in all the 
treatments IC50 higher than the range of μM [Simeone et al., 2011]. 
 
2.1.3 Nuclelipidis based-Ru co-aggregate with the neutral liposome POPC 
It is important to highlight that the complexes DoHuRu, ToThyRu and HoThyRu, as wells 
as ruthenium derivatives of low molecular weight, are not very stable, showing phenomena 
of degradation, within a few hours in saline buffer or a few days in pure water, that, as 
illustrated in the Figure 20, are visible to the naked eye because the solution changes color 
from yellow to dark green. Moreover, after 5 h in saline and 78 h in pure water, they form 
small dark precipitates. These complexes are susceptible to hydration and hydrolysis due to 
the presence of chlorine ions and the residual dimethyl sulfoxide (DMSO). In particular, 
the EPR method showed that the single hydrophobic tail, as in the complexes ToThyRu 
and HoThyRu, destabilizes more the phospholipid bilayer respect to the presence of two 
hydrophobic chains (DoHuRu) [Mangiapia et al., 2012]. In order to increase their stability, 
the nucleolipids ruthenium-based aggregates were mixed with the lipid POPC, well known 
for its ability to form stable liposome [Stano et al., 2004]. This co-aggregation allows 
modulating the quantity of metal to be included and ensure the protection from 
extracellular degradation. Previous experiments have excluded the cytotoxicy of POPC 
alone and of the co-aggregates without ruthenium (ToThy/POPC, DoHu/POPC, 
HoThy/POPC), confirming the usability of POPC in the preparation of pharmaceutical 
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formulations. Moreover, the co-aggregates, including even the metal, have resulted stable 
for months [Mangiapia et al., 2012]. 
 
 
Mangiapia et al., Biomaterials. 2012; 33(14):3770-82. 
Fig.20. DoHuRu just prepared in pure water (left) and after 120 h (at the center); DoHuRu 
complexed with POPC the physiological solution, 10 months after (right). 
The POPC self-assembled prevalently in the liposomal vesicles, more stable than the 
micelles. The data obtained through the methods SANS and DLS are similar to those 
obtained with the POPC only, since the amount of this compound is very high compared to 
that of ruthenium (molar ratio 85:15). On the other hand, this means that the nucleolipids 
do not destabilize the structure of the POPC liposomes. In addition bioscreening in vitro, 
showed that the POPC liposomes ruthenium-based had similar effects to that of AziRu, 
although they enclose only 15% of ruthenium in moles. This means that these formulations 
have the same cytotoxicity of AziRu, but at a ruthenium concentration 6 times smaller. 
Also, by fluorescence experiments, they showed an efficient kinetics of cellular uptake, 
presumably with a localization in the cytoplasm [Mangiapia et al., 2012]. 
 
2.1.4 Nuclelipidis based-Ru co-aggregate with the cationic liposome DOTAP 
In order to enhance the antineoplastic activity, we tested the coaggregation of the 
nucleolipids with the cationic lipid DOTAP in the mixture 50:50 (Fig.21). The cationic 
liposomes are emerged as alternative to the neutral vesicles, and could bring several 
advantages, first of all the major interaction with the cell membranes [Wiethoff et al., 
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2001]. In our case, the cationic charge of DOTAP can also enhance the aggregation with 
the negative charges of the nucleolipids forming the amphiphilic ruthenium complex, as 
described for the formation of DOTAP complex with the DNA [Hayes
 
et al., 2006] and 
thus make a more stable liposome. These aggregated are well chemically characterized by 
different techniques, like dynamic light scattering (DLS), small angle neutron scattering 
(SANS), neutron reflectivity and zeta potential, and electron paramagnetic resonance 
(EPR), and have presented high stability in aqueous environment even at high Ru-complex 
content. 
 
Fig. 21. Simplified representation of DOTAP liposome ruthenium-based 
 
2.2 AIM 
Previous results obtained by our research group have shown that the co-aggregation 
between amphiphilic nucleolipids and the neutral lipid POPC forms stable liposomes that 
are good candidate for the delivery of the ruthenium complex. In fact, the effect of this 
"nanovectorization" is an increment of the bioactivity of AziRu. Also, in order to optimize 
this system we made a cationic liposome, based on DOTAP lipid. The aim of this work is 
thus the in vitro biological characterization of the ruthenium-based DOTAP liposome. 
Considering the promising results about the stability of such liposomes, the first objective 
was to explore the bioactivity of the ruthenium-based DOTAP liposomes, as well as their 
cellular uptake, and to compare the data with those previously obtained by the co-
aggregation with the neutral liposomes. For this purpose, cell viability assays and 
fluorescence microscopy experiments have been conducted. Indeed, it assessed that these 
compounds have antiproliferative effects and this is imputable exclusively to the 
vehiculated active principle. The question is what happens after the cellular uptake of the 
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liposomes, when the metal is released into the cells. In fact, as well as the other ruthenium 
compounds, it is not fully understood their mechanism of action. On the other hand, it is 
probable that, unlike NAMI-A [Bergamo and Sava 2015], the ruthenium-delivered 
complex interacts more with intracellular than extracellular targets. In addition, the 
liposomal formulations and the nucleolipidic scaffold could be responsible of different 
pharmacodynamics. Thus, in view of a more in-depth analysis of the specific target 
involved in their mechanism of action, the second objective was to identify the cell death 
pathways induced by both cationic and neutral liposomes, by means of the FACS analysis 
of autophagy and apoptosis, the evaluation of the DNA damage, and the Western Blot 
analysis of the caspases expression.  
 
2.3 MATERIALS AND METHODS 
2.3.1 Cell cultures 
Human WiDr epithelial colorectal adenocarcinoma cells, MCF-7 breast adenocarcinoma 
cells, and rat C6 glioma cell line were purchased from ATCC (American Type Culture 
Collection, Manassas, Virginia, USA). C6 cells were grown in Dulbecco’s modified 
Eagle’s medium (DMEM, Invitrogen, Paisley, UK) containing high glucose (4.5 g/l), while 
MCF-7 and WiDr were grown in RPMI 1640 medium (Invitrogen, Paisley, UK). Media 
were supplemented with 10% fetal bovine serum (FBS, Cambrex, Verviers, Belgium), L-
glutamine (2 mM, Sigma, Milan, Italy), penicillin (100 units/ml, Sigma) and streptomycin 
(100 mg/ml, Sigma), according to ATCC recommendations. All cells were cultured in a 
humidified 5% carbon dioxide atmosphere at 37 °C. 
 
2.3.2 Cell viability 
To evaluate the antiproliferative activity of the nanovectors, both the MTT Assay and the 
cell count were performed. WiDr, MCF-7 and C6 cells were washed with PBS buffer 
solution (Sigma), collected by trypsine (Sigma) and then inoculated in a 96-microwell 
culture plates at density of 10
4
 cells/well. Cells were allowed to grow for 24 h, then the 
medium was replaced with fresh medium and cells were treated for further 48 h with a 
range of concentrations (10→100 µM) of AziRu and of the liposomes DOTAP, 
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DoHuRu/DOTAP, HoThyRu/DOTAP and ToThyRu/DOTAP. Cell viability was evaluated 
with the MTT assay procedure, which measures the level of mitochondrial dehydrogenase 
activity using the yellow 3-(4,5- dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium 
bromide (MTT, Sigma) as substrate. The assay was based on the redox ability of living 
mitochondria to convert dissolved MTT into insoluble purple formazan. Briefly, after the 
treatments the medium was removed and the cells were incubated with 20 μl/well of an 
MTT solution (5 mg/ml) for 1 h in a humidified 5% CO2 incubator at 37 °C. The 
incubation was stopped by removing the MTT solution and by adding 100 μl/well of 
DMSO to solubilize the purple formazan. Finally, the absorbance was monitored at 530 nm 
by using a microplate plate reader (iMark microplate reader, Biorad, Milan, Italy). For the 
count of the viable cells, the method of Trypan Blue Exclusion was used. Briefly, cells 
were grown at 1.0 ×10
5
 in 48 well-plate for 24 h and treated with the compounds, at the 
same condition used for the MTT assay. The cells are then trypsinized, centrifuged and 
resuspended in the medium. An aliquot of cell suspension (10 μl) is mixed 1:1 with Trypan 
Blue and the number of viable cells was evaluated using an automatic counter (TC20 
Automated Cell Counter, Bio-Rad, Milan, Italy), providing an accurate and reproducible 
total count of the cells and the live/dead ratio. The calculation of the concentration required 
to inhibit the cell the viability by 50% (IC50), arising both of MTT assay and cell count, is 
based on plots of data carried out in triplicates and repeated three times. IC50 values were 
obtained using a dose-response curve by nonlinear regression using a curve fitting 
program, GraphPad Prism 5.0, and are expressed as mean ± SEM. 
 
2.3.3 Fluorescence microscopy  
To evaluate the cellular uptake of the liposome, rhodamine B lipid derivative, 1,2- 
dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) 
ammonium salt (λex 560 - λem 583 nm) (Fig.22), was used as a fluorescent probe by 
adding 2% mol during the synthesis of DoHuRu/DOTAP liposome. To directly follow the 
ruthenium fate in the cell, the fluorogenic group of the dansyl (λex 370 - λem 450 - 550 
nm) was used, directly bound to the ruthenium complex (HoThy-DansRu) (Fig.23), that is 
then normally co-aggregated with DOTAP. Sterile coverslips were placed in twenty-four-
well plates. MCF-7 cells were seeded at a concentration of 5x10
4
/ml in the same twenty-
four-well plates. Following a growth period of 24 h at 37 °C in RPMI 1640 medium 
 Ruthenium-based nanovectors: comparison between neutral and cationic liposomes  50 
 
containing 10% FBS, the medium was replaced with serum-free RPMI 1640 medium, 
which was followed by the addition of fluorescent liposomes at final concentration 100 µM 
or free PBS saline solution to each well. The cells were incubated for additional times (30 
min, 1, 3 and 6 h) with liposomes and washed with PBS three times to remove 
unassociated liposomes. The cells were then fixed at room temperature in 4% 
paraformaldehyde for 20 min. After washing with PBS three times, the cells were treated 
with diaminophenylindole (DAPI) (Sigma) to stain the cell nuclei. The coverslip from each 
well was mounted onto a glass microslide with 80% fluorescence-free glycerol mounting 
medium. Finally, the interaction of liposomes with MCF-7 cells and the cellular uptake 
was monitored using a fluorescent microscope (Leica Microsystems GmbH, Wetzlar, 
Germany) to visualize DAPI (345/661 nm) and fluorescent liposomes (557/571 nm). 
Images were taken using an AxioCam HRc video-camera (Zeiss) connected to an Axioplan 
fluorescence microscope (Zeiss) using the AxioVision 3.1 software. 
 
Fig.22. Molecular structure of rhodamine-based fluorescent probe  
 
Fig. 23. Molecular structure of HoThyDansRu 
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2.3.4 Flow cytometric analysis of autophagosomes formation  
To quantify the induction of the autophagic process, MCF-7 cells treated with the various 
compounds, were stained with the autofluorescent agent monodansylcadaverine (MDC), a 
selective marker for autophagic vacuoles (AVOs) and especially autolysosomes. Treated 
cells were incubated with 50 μM MDC in PBS at 37°C for 15 min. After incubation, cells 
were washed with PBS, and immediately analyzed by flow cytometry. All fluorescences 
were analyzed with a FACScalibur flow cytometer (Becton Dickinson). The fluorescent 
emissions were collected through a 530 nm band pass filter (FL1 channel). At least 10 000 
events were acquired in log mode. For the quantitative evaluation of MDC, CellQuest 
software (Becton Dickinson) was used to calculate mean fluorescence intensities (MFIs). 
The MFIs were calculated by the formula (MFI treated/MFI control), where MFI treated is 
the fluorescence intensity of cells treated with the various compounds and MFI control is 
the fluorescence intensity of untreated and unstained cells. Values reported in the figures 
are the means ± S.D.s from three independent experiments. 
 
2.3.5 FACS analysis of apoptosis  
Annexin V-FITC (fluorescein isothiocyanate) was used in conjunction with a vital dye, 
Propidium Iodide (PI). Propidium Iodide is a specific dye for the DNA, excluded by the 
cells that conserve the integrity of the membranes, whereas it stains DNA in the cells that 
have damaged membranes. Annexin V/FITC has a high specificity to bind the molecules of 
phosphatidylserine (PS), a phospholipid of cellular membrane normally exposed on the 
cytoplasmic side. The externalization of PS is a key event of the first state of apoptosis that 
lastly allows the recognition by the phagocytes. Thus, by cytofluorimetric analysis of the 
double fluorescence, it is possible to identify the viable cells (negative to both dyes), the 
necrotic cells (positive only to PI), the early apoptotic cells (positive only to Annexin V-
FITC), and the late apoptosis/necrotic cells (positive to both PI and Annexin V-FITC)  
[Wlodkowic et al., 2009], as illustrated in Fig. 24. Briefly, cells were incubated with 
Annexin V–FITC (MedSystems Diagnostics, Vienna, Austria) and propidium iodide 
(Sigma) in a binding buffer (10 mM Hepes, pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM 
MgCl2, 2.5 mM CaCl2) for 10 min at room temperature, washed and resuspended in the 
same buffer. Analysis of apoptotic cells was performed by flow cytometry (FACScan, 
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Becton 4 Dickinson). For each sample, 2 × 10
4
 events were acquired. Analysis was carried 
out by triplicate determination on at least three separate experiments. 
 
www.lifesci.dundee.ac.uk 
Fig. 24. Double method of PI and Annexin V detection of apoptosis by FACS analysis 
 
2.3.6 DNA fragmentation assay 
MCF-7 cells were grown on standard sterile plastic 60 mm culture dishes by plating 5x10
5
 
cells. After 24 h of growth the cells were treated for 48 h with IC50 doses of AziRu, 
DoHuRu/POPC, DoHuRu/DOTAP. Then, the cells were collected and the pellets were 
resuspended in lysis buffer (50 mM Tris-HCl, pH 7.5, 5 mM EDTA, 100 mM NaCl, 1% 
SDS, 0.5 mg/mL Proteinase K) and incubated at 50°C. After 1 h incubation, 10 mg/mL 
RNase was added to the lysates and incubated for 1 h at 50°C. DNA was precipitated with 
NaOAc pH 5.2 and ice cold 100% EtOH and centrifuged at 14000 × g for 10 min. Pellets 
were dissolved in TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA). A 20 µL aliquot of 
each DNA sample was analyzed on a 1.5 % agarose gel stained with ethidium bromide and 
visualized under UV light. 
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2.3.7 Western blot analysis of caspases expression 
MCF-7 cells, treated with the IC50 concentration of ruthenium-based nucleolipids co-
aggregated in DOTAP for 48 and 72 h, were lysed at 4 °C in the buffer containing 10 mM 
Tris-HCl, pH 7.6, 50 mM NaCl, 1% Triton X-100, and protease inhibitor cocktail (Roche 
Diagnostics, Mannheim, Germany). Cell debris were pelleted by centrifugation at 4 °C for 
20 min at 14,000 × g, and protein concentration of cell lysate was determined by the Bio-
Rad protein assay (Bio-Rad, Milan, Italy). Samples containing 40 μg of proteins were 
separated on a 12% SDS-polyacrylamide gel and electrotransferred onto a nitrocellulose 
membrane (Amersham Biosciences, Little Chalfont, Buckinghamshire, UK) using a Bio-
Rad Transblot (Bio-Rad). Proteins were visualized on the filters by reversible staining with 
Ponceau-S solution and destained in PBS. After blocking for 1 h at room temperature in 
5% milk in Tris-Buffered Saline and Tween 20 (TBS-T), membranes were incubated with 
1:1,000 dilutions of the primary antibodies to caspase-9, caspase-8 and tubulin (Cell 
Signaling, Beverly, MA, USA). Membranes were then washed 3 times with TBS-T before 
being incubated with appropriate horseradish peroxidase conjugated secondary antibodies. 
The immunocomplexes were visualized by the ECL chemoluminescence method (ECL, 
Amersham Biosciences) and analyzed by an imaging system (ImageQuantTM 400, GE 
Healthcare Life Sciences). Densitometric analysis was performed using the GS-800 
imaging densitometer (Bio-Rad). Tubulin antibody was used to normalize the results. 
 
2.3.8 Statistical analysis 
All data were presented as mean ± SEM. The statistical analysis was performed using 
Graph-Pad. Prism (Graph-Pad software Inc., San Diego, CA) and ANOVA test for 
multiple comparisons was performed followed by Bonferroni’s test.  
 
 
 
 
 
 Ruthenium-based nanovectors: comparison between neutral and cationic liposomes  54 
 
2.4 RESULTS  
2.4.1 Antiproliferative activity 
The cell survival index curves (Fig.25) demonstrate that, as expected, the DOTAP 
liposome ruthenium-free showed no significant interference with the cell viability and 
proliferation. Interestingly, the three amphiphilic ruthenium complexes co-aggregated with 
DOTAP are much more active than the precursor AziRu. In fact, the corresponding IC50 
values referred at the ruthenium concentration enclosed in the nanovector (50% in moles) 
are significantly decreased, as highlighted also by the potentiating factors (Tab.1), 
calculated as the  ratio of  IC50 values of AziRu and the nanovectors in the corresponding 
cell lines. For example, the nanovectors are about 20 times more effective than AziRu on 
MCF-7 cells (IC50 15 μM and 305 μM, respectively). Presumably, their higher anticancer 
activity with respect to low molecular weight ruthenium complexes is the result of an 
enhanced cellular uptake efficiency due to the "nanovectorization", as well as of the 
capacity of Ru(III) nucleolipidic aggregates themselves in inhibiting cell growth and 
proliferation. According with the previous results [Mangiapia et al., 2012], Ru(III) 
derivatives are more active on MCF-7 cells than against other cancer cells. However, the 
antiproliferative effect observed in rat C6 glioma cells, a current model system useful for 
the evaluation of new therapies for the treatment of one of the most resistant tumor, the 
glial neoplasm, [Grobben et al, 2002] is an important indication on the wide spectrum of 
action of these ruthenium-nanovectors .  
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Fig. 25. Cell survival index values, evaluated by MTT assay and total cell count, in C6, 
WiDr and MCF-7 cell lines incubated for 48 h with DOTAP, with different Ru-containing 
formulations and with AziRu. On the right, the corresponding concentration-effect curves 
obtained by normalizing for the actual amount of ruthenium contained in the liposomes.
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Tab.1 IC50 values reported as mean ± SEM. In bold, the Potentiating Factors (PF) of the 
nucleolipidic ruthenium complexes in DOTAP respect to Azi-Ru are shown, calculated as 
the ratio of IC50 values of DoHuRu/DOTAP, HoThyRu/DOTAP, and To-ThyRu/DOTAP 
complexes to the IC50 of AziRu. 
 
              2.4.2 Cellular uptake  
For both ruthenium and platinum complexes, the cytotoxicity profiles are significantly 
correlated with the rate of cellular uptake, for which their lipophilicity is a favorable 
parameter [Tan et al., 2011]. In order to evaluate the kinetics of accumulation of the 
cationic liposomes ruthenium-based into human  MCF-7 cancer cells, the fluorescent probe 
Rhodamine was inserted in the liposomal bilayer of DoHuRu/DOTAP. These experiments 
have been also performed by exposing the cells to the rhodamine B adduct alone under the 
same in vitro experimental conditions, like negative control. In the microphotographs 
reported in Figure 26, the blue areas indicate the cells nuclei stained by DAPI, whereas the 
green areas represent the rhodamine localization. As shown by time-course experiments 
starting after 30 min of incubation, DoHuRu/DOTAP liposome seems highly able to cross 
the cell membranes, trough a very fast process of internalization. By merged images 
(Merge), where the emission of the two fluorophores is overlapped, it is also more clear 
again that the liposome enters in the cells, and arrives in the proximity of the nuclei too. By 
means of their lipid properties, it is possible that the Ru complexes/DOTAP 
nanoaggregates interact with the cells directly via membrane fusion and/or by endocytosis. 
These processes apparently occur by nonspecific patterns involving multiple molecular 
mechanisms, probably starting from charge attraction and ultimately leading to close 
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contact with the membrane [Zabner et al., 1995; Bailey et al., 1997].  Also, at less time of 
incubation, this liposome shows a more massive uptake than the same system formed by 
the neutral lipid POPC [Mangiapia, et al., 2012]. This proves that the positive charge of the 
liposome improves its capacity to interact with the negative charged components of the 
plasmatic membrane, such as proteoglycans [Wiethoff et al., 2001].  
To further investigate cellular uptake, MCF-7 cells were treated with the dansyl-labeled 
ruthenium complex HoThy- DansRu coaggregated with DOTAP under the same conditions 
used for HoThyRu, ToThyRu, and DoHuRu. In this way, the fate of the active ruthenium 
complex can be directly followed, by analyzing its location after nanocarriers application 
to the cells. According with the above mentioned results, fluorescently labeled 
HoThyDansRu localizes rapidly within the cells, and the microphotographs in Figure 27 
show a growing time-course accumulation. The fluorescence emission analyzed seems also 
suggest that the complexes loaded in DOTAP liposomes enter the cytoplasm before being 
predominantly delivered to discrete foci in the perinuclear compartment; moreover, 
although attenuated by DAPI nuclear staining, dansyl-dependent fluorescence emission is 
also detectable in the nuclei area. Combining the results of these two kinds of labeling, one 
for the DOTAP bilayer, and the other for the nucleolipidic component, it is possible to 
presume a rapid phenomenon of degradation of the whole liposome in the intracellular 
space and a fast release of the "active agent" in the cytoplasm. This assumption could 
explain the extensive rhodamine-associated fluorescence and the related generation of 
discrete dansyl-associated foci. Also, the accumulation of dansyl fluorescence in proximity 
to the nuclei suggests a possible interaction between the nucleolipid HoThyDansRu and the 
nuclear membranes by mechanism like adsorption, lipid mixing and lysis, as already 
described for negative charged vesicles [Lawaczeck et al., 1987]; thus this consideration 
opens the scenario to the different possible fates of ruthenium-based nucleolipids after 
liposomes delivery, like the interaction with the nuclear membranes and subsequent 
accumulation of the metal in the nucleus, but without excluding the binding with targets in 
other cellular compartments. However, given the wide range of possible modification to 
which the ruthenium complexes can be subjected in the cellular environments, such as the 
ligand-exchange reactions or changing of the redox state, further studies will be done to 
individuate what is/are the effective active specie/species responsible for the 
antiproliferative effects.  
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Fig.26. Fluorescent microphotographs of monolayers showing the cellular uptake of 
liposomes by human MCF-7 breast adenocarcinoma cells. DAPI is used as a nuclear stain 
(shown in blue). Rhodamine-dependent fluorescence (Rhod) of DoHuRu/DOTAP 
liposomes is shown in green. In merged images (Merge), the two fluorescent emissions are 
overlapped. 
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Fig.27. Fluorescent microphotographs of monolayers showing the cellular location of 
dansylated-HoThyDansRu complex into human MCF-7 breast adenocarcinoma cells 
subsequent to nanocarriers application. DAPI is used as a nuclear stain (shown in blue). 
Dansyl-dependent fluorescence (Dans) of HoThyDansRu/DOTAP liposomes is shown in 
red. In merged images (Merge), the two fluorescent emissions are overlapped. 
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2.4.3 Apoptosis and autophagy activation 
To evaluate the pathways of cell death involved in the antiproliferative effect of the neutral 
and cationic ruthenium-nanovectors, the MCF-7 cells, which are among the most sensitive 
to these compounds, were treated for 48 and 72 h with DoHuRu/POPC and 
DoHuRu/DOTAP with concentrations equal to IC50 values. The analysis of the formation 
of autophagosomes was performed by the Monodansylcadaverine (MDC) staining, an 
autofluorescent agent specific for the autophagolysosome, and flow cytometric evaluation 
of the associated fluorescence. The occurrence of autolysosomes, resulting from 
lysosomes-autophagosomes fusion, exclusively characterizes late steps in the autophagic 
cell death process. As showed in the Figures 28 and 29, the cationic DoHuRu/DOTAP 
formulation induces a significant (p<0.001) increase in the Mean Fluorescence Intensity 
(MFI) that grow over time (4.3 and 5.8-fold at 48 and 72 h, respect to control untreated 
cells), indicating a strong formation of the MDC-labeled vacuoles. Conversely, no 
autolysosomes formation was detected after DoHuRu/POPC treatment, at least up to 72 h.  
 
The FACS analysis of apoptosis was carried out by the double staining with Annexin V-
FITC and Propidium Iodide. This method has the advantage of discriminating not only 
between viable, necrotic and apoptotic cells, but also between the early and late stages of 
apoptosis. Propidium Iodide is a specific dye for the DNA, excluded by the cells that 
conserve the integrity of their membranes, whereas it stains DNA in the cells that have 
damaged membranes. Annexin V/FITC has a high specificity to bind the molecules of 
phosphatidylserine (PS), phospholipid of cellular membrane normally exposed on the 
cytoplasmic side. The externalization of PS is a key event of the first state of apoptosis that 
lastly allows the recognition by the phagocyte. Thus, by cytofluorimetric analysis of the 
double fluorescence, it is possible to identify the healthy cells (negative to both dyes), the 
necrotic cells (positive only to PI), the cells in early apoptosis (positive only to Annexin V-
FITC), the cells in late apoptosis (positive to both PI and Annexin V-FITC). The FACS 
analysis shows that after 48 h of treatment with the cationic nanovector DoHuRu/DOTAP, 
a consistent percentage of cells (46.5 %) are already in the phase of late apoptosis (Fig. 
30), and that this percentage increases at 72 h of treatment (82.1 %) (Fig. 31). These results 
confirm that, despite the fast kinetics of uptake, the processes triggered by the active agent 
persist over time, involving probably different mechanism of cell signaling, which in turn 
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lead to the induction of cell death. Also, the simultaneous and growing presence of 
autophagy and apoptosis at long time suggests that no mechanisms of protection are 
inducted by the autophagy that, contrarily, may itself induce apoptosis [Maiuri et al., 
2007]. On the other hand, the treatment with neutral liposome DoHuRu/POPC (Fig. 30 and 
31) induces early apoptosis (35.8 % at 48 h and 35.2% at 72 h) and just a little percentage 
of cells arrives in the phase of late apoptosis (13.6 % at 48 h, 37.4% at 72h). The slower 
kinetics of apoptosis induction as well as the absence of autophagy in the cells treated with 
the neutral liposomes, indicates that these systems interfere with the cell viability in a 
different way respect to the cationic nanovectors. Moreover, this result emphasizes the role 
of the liposomes in the capacity to deliver the drug but also in the explication of the 
ruthenium mechanism of action. Thus the liposome formulation could be not only passive 
carriers for the ruthenium complexes, but a system that interferes with the affinity of the 
ruthenium with the molecular targets.  
 
To confirm the apoptosis, DNA was extracted from MCF-7 cells treated with IC50 
concentrations of nanovectors and AziRu and loaded on agarose gel. The gel in Figure 32 
shows that the DNA extracted from cells treated with the cationic liposome is degraded to 
form fragments called "ladder" of 180 bp and multiples, typical of the late stage of 
apoptosis. Really, MCF-7 is one of the human breast cancers known to be resistant to some 
chemotherapeutics due to deletion in the CASP-3 gene that leads to an innate deficiency of 
caspase-3 [Jänicke et al., 1998]. Caspase-3 cleaves a variety of important cellular proteins 
and it is ultimately responsible for apoptotic DNA fragmentation. Different patterns of 
DNA cleavage are involved in the apoptosis process, like the formation of large DNA 
fragments coupled to single-strand cleavage, of which the specific responsible enzymes are 
not yet definitively individuated [Bortner et al., 1995]. Also, DNA fragmentation in MFC-
7 cells due to cytotoxic agents may correlate with the activation of different apoptotic 
pathways and other effector caspases, such as caspases -6 or -7 [Liang et al., 2001]. 
Moreover, it cannot be excluded that this event is due to a direct effect of the capacity of 
the ruthenium complex to intercalate the DNA, as occurs in the interaction between a di-
nuclear Ru(II) polypyridyl complex and a plasmid model [Liu et al., 2016]. Interesting, we 
can note also a high level of DNA fragmentation with AziRu, but the effective used dose to 
have the equal concentration/effect (IC50) to the liposomes is very high (305 and 13 µM 
respectively). This confirms the efficiency of the liposomes for the drug delivery and 
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suggests that the mechanism of action that leads to apoptosis induction is explicated inside 
the cells by binding targets that are not yet known, but that, in consideration of the results 
obtained at the moment, could be multiples, such as DNA and protein/enzyme. On the 
other hand, flow cytometric analysis showed that DoHuRu/POPC produces just a bland 
activation of apoptosis and autophagy pathways. In according with these data, DNA 
fragmentation assay showed that only a little percentage of DNA is fragmented by neutral 
liposomes. Considering that the rapport of concentration/effect is the same, this means that 
the liposome formulation and its interaction with the cells influence the mechanism of cell 
death induced by ruthenium.  
 
Ascertained that the cationic nanovectors cause cell death prevalently by apoptosis, to 
better characterize this event we started an analysis of caspases expression. This 
preliminary screening of apoptotic factors was focused on the activation of caspase-8 and -
9, the two initiators caspases of the extrinsic and intrinsic pathway of apoptosis, 
respectively. In this way, we have been able to discriminate between the involvement of 
these two kinds of apoptosis pathways, evaluating the specific activation of the intrinsic 
apoptotic pathway (Fig. 33); it is also called mitochondrial pathway because the activation 
of the caspase-9 depends on the change in the permeability of the mitochondrial 
membrane, that in turn is due to various stimuli, such as DNA-damaging agents, overload 
of Ca
2+
, deprivation of growth factors, oxidants and microtubule-targeted drugs [Baig et 
al., 2016]. This type of apoptosis could be preferable in the prospective of making a stealth 
drug delivery system, because it doesn't suppose, unlike the extrinsic apoptosis, a 
participation of extracellular factors, often involved in the immune responses [Fulda and 
Debatin, 2006]. However, further investigations on the expression of other apoptotic 
factors are in progress, in order to obtain a complete view of the apoptotic cascade 
involved in the activity of ruthenium-based nanovectors. 
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Fig.28. Flow cytometric analysis of autophagosomes formation (MDC incorporation) in 
MCF-7 treated with IC50 concentrations of DoHuRu/DOTAP or DoHuRu/POPC for 48h. 
Values are the means of three independent experiments (±S.D.).  
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Fig. 29. Flow cytometric analysis of autophagosomes formation (MDC incorporation) in 
MCF-7 treated with IC50 concentrations of DoHuRu/DOTAP or DoHuRu/POPC for 72h. 
Values are the means of three independent experiments (±S.D.).  
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Fig.30. Apoptosis was evaluated by FACS analysis, after cell labeling with PI and FITC-
Annexin V. MCF-7 cells were both unlabeled and untreated (A), labeled and not treated 
(B), treated with IC50 concentrations of DoHuRu/DOTAP (C) or DoHuRu/POPC (D) for 
48h. The lower left quadrants of each panels show the viable cells, which exclude PI and 
are negative for FITC-Annexin V binding. The upper left quadrants contain the non-viable, 
necrotic cells, negative for FITC-Annexin V binding and positive for PI uptake. The lower 
right quadrants represent the cells in early apoptosis, that are FITC-Annexin V positive and 
PI negative. The upper right quadrants represent the cells in late apoptosis, positive for 
both FITC-Annexin V binding and for PI uptake. The experiments were performed at least 
three times with similar results. 
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Fig.31. Apoptosis was evaluated by FACS analysis, after cell labeling with PI and FITC-
Annexin V. MCF-7 cells were both unlabeled and untreated (A), labeled and not treated 
(B), treated with IC50 concentrations of DoHuRu/DOTAP (C) or DoHuRu/POPC (D) for 
72 h. The lower left quadrants of each panels show the viable cells, which exclude PI and 
are negative for FITC-Annexin V binding. The upper left quadrants contain the non-viable, 
necrotic cells, negative for FITC-Annexin V binding and positive for PI uptake. The lower 
right quadrants represent the cells in early apoptosis, that are FITC-Annexin V positive and 
PI negative. The upper right quadrants represent the cells in late apoptosis, positive for 
both FITC-Annexin V binding and for PI uptake. The experiments were performed at least 
three times with similar results.  
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Fig.32. DNA fragmentation assay in MCF-7 cells, treated or not (Ct) for 48 h and 72 h 
with IC50 doses of DoHuRu/POPC or DoHuRu/DOTAP and  AziRu alone.   
 
 
Fig.33. Western Blot Analysis of Caspase-8 and Caspase-9 activation in MCF-7 cells 
untreated and treated with DoHuRu/DOTAP for 48 and 72 h; In the graph, the 
quantification of the cleaved/full lenght caspase-8 and caspase-9, calculated as percent of 
the control.  
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2.5 CONCLUSIONS 
Previous results obtained on the POPC liposomes, have shown the efficacy of the 
"nanovectorization" on the activity of the low molecular weight complex AziRu, analog of 
NAMI-A. NAMI-A showed low cytotoxicity for the primary tumor, but is one of a few 
antimetastatic drugs. This means that the lack of anticancer activity is due to a poor 
interaction of the compounds with targets within the cells; when AziRu is vehiculated 
inside the cells, it can better explicate its antiproliferative effects, as demonstrated for other 
polymeric system ruthenium-based [Lu et al., 2015; Duan et al., 2015]. Now we 
demonstrated the efficacy of cationic nanovector, formed by the lipid DOTAP, to carry the 
ruthenium complexes. Moreover, it induces both autophagy and apoptosis, suggesting the 
activation of multiple pathways of cell death. The coupled results of viability assay and 
cellular uptake show that cationic liposomes are a good system to deliver the ruthenium 
complexes, also in a stronger way respect to neutral liposome, due to the greater interaction 
between the cationic lipid and the negative component of the cell surface. This is in 
agreement with a study showing that the fusion of cationic liposomes with the cancer cell 
membrane, due to the attraction of charges, is easier when the cells expose 
phosphatidylserine on their surface [Stebelska et al., 2006]. Since DoHuRu/DOTAP has 
shown to give in the MCF-7 cells a rapid activation of the early state of apoptosis, typically 
characterized by phosphatidylserine externalization, the hypothesis is that its cellular 
uptake can increase over time, like a positive feedback mechanism. This event could 
explain also the poor activation of the late state of apoptosis by the neutral liposome 
DoHuRu/POPC, as a lack of increment of the cellular uptake, as suggested by the faster 
kinetics of fluorescent accumulation after treatment of the cells with the rhodamine-labeled 
cationic liposomes [Mangiapia et al., 2012]. On the other hand, the different profiles of cell 
death in the cells treated with the neutral and the cationic liposome provides evidences that 
the nanocarriers, by interfering with the uptake of the ruthenium complex, could change its 
target-specificity. Thus, the inclusion in the nanocarriers could amplify the scenario of the 
employment of these complexes, and could represent a strategy to overcome the drug 
resistance. All together these results demonstrate that the ruthenium-based DOTAP 
liposomes are a good alternative to the low molecular weight ruthenium complexes. In 
Figure 34 is illustrated an hypothetical mechanism of cellular interaction suggested for 
cationic ruthenium-based nanovectors. However, there is still much to investigate about 
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their mechanism of action and the structure-activity relationship, as well as the 
physiological implications and the metabolic targets in vivo will be tested. 
 
 
 
Fig.34. Hypothetical mechanism of cellular interaction proposed for cationic ruthenium-
based nanovectors: the liposomes could specifically direct by the passive targeting to the 
cancer cells, whereas interact with the cell membranes by adsorption and/or endocytosis. 
Inside the cells, chemical modifications might occur, leading to one or more active species 
of ruthenium complexes, which can have multiple targets, in the nucleus and/or in the 
cytoplasm, leading lastly to the induction of autophagy and apoptosis pathways. In 
addition, the early state of apoptosis is characterized by the exposition of the 
phosphatidilserine (PS) from the inner membrane to the surface, event that in turn could 
improve the interaction of the cationic liposome with the cells undergoing apoptosis.  
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3. DOTAP-TothyCholRu: cholesterol 
improves the cellular uptake 
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3.1. INTRODUCTION 
3.1.1. The role of cholesterol in natural and biomimetic membranes 
Cholesterol is a fundamental constituent of the organism; it is a key component of 
biological membranes and precursor of bile salts, vitamins and all steroid hormones. 
Cholesterol has a critic role in keeping the fluidity of the cell membrane: on the one hand 
reduces the freedom of movement of the chains, on the other hand prevents intermolecular 
bonds between lipids and thus the rigidity of the membranes [Chapman, 1975]. For this 
reason many researches are focused on the design of bio-mimetic model membranes 
system that, exploiting the advantages of the similarity to the biological membranes, could 
be a new strategy for the drug delivery. Thus the inclusion of cholesterol in membrane 
models can have different advantages. It increases the rigidity of the lipid bilayer and 
reduces its instability in the blood, due to the serum protein binding [Mabrey et al., 1978]. 
Also, it is recognized by receptors of low-density lipoprotein (LDL) facilitating the 
endocytosis [Krieg et al., 1993], and represents a highly biocompatible system [Lacko et 
al., 2007]. Some interesting examples of the inclusion of cholesterol in biological systems 
are already reported in literature: end-modification with a cholesterol motif has been 
effectively applied to biologically active oligonucleotides [Musumeci and Montesarchio, 
2012]; different modifications of lipid architectures introducing cholesterol are reported as 
good strategy to increase the transfection processes [Bajaj et al., 2008; Bajaj et al., 2007]; 
DOTAP liposomes including cholesterol as vector for gene transfection, are nowadays in 
clinical trials for the treatment of lung cancer [Lu et al., 2012]. Some studies concerning 
liposomes interaction with membrane show also a specific cholesterol/lipid ratio, similar to 
the one reported for the plasma membrane of animal cells, to obtain the optimal cellular 
fusion [Hosta-Rigau et al., 2013; Moghaddam et al., 2011]. In the contest of cancer 
therapy, the use of cholesterol is not only useful for the formation of a biomimetic 
membrane, but also to make a sort of active targeting. In fact cancer cells need of an excess 
of cholesterol [Murtola et al., 2012] that have an important impact on tumor development, 
cell migration and angiogenesis [Cruz et al., 2013; Buchwald, 1992]. Exploiting the altered 
metabolism of cholesterol in cancer cells, it is possible to make a strategy properly defined 
by Lacko et al. “Trojan horse” approach [Lacko et al.,2007]; in fact, successful synthetic 
lipoproteins as drug delivery platform for anti-cancer agents are reported in literature 
[Sabnis and Lacko, 2012]. 
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3.1.2. ToThyCholRu/DOTAP 
As an evolution of the previous work on ruthenium-based cationic liposome (Chapter 2), 
we here performed the biological characterization of the ruthenium nucleolipid including 
cholesterol, named ToThyCholRu, co-aggregated with the lipid DOTAP. In particular, the 
cholesterol is bound with the oxidril 3' of the ribose of the nucleolipid ToThyRu. The so-
formed ToThyCholRu (Fig.35), intrinsically negatively charged, is lodged in the cationic 
DOTAP bilayer (Fig.36). This liposome contains a final concentration of ToThyCholRu 
equal to 30% in moles and results stable for several months. This system has been 
characterized using dynamic light scattering (DLS), small angle neutron scattering 
(SANS), neutron reflectivity (NR) and electron paramagnetic resonance (EPR) techniques. 
Due to the high affinity of cholesterol with phospholipids, ToThyCholRu could easily 
interact with the cell membranes, facilitating the ruthenium complex internalization.  
 
Fig. 35. Molecular structure of the nucleolipid ToThyCholRu 
 
Fig. 36. Graphical representation of how the ruthenium complex anchored to the 
cholesterol-functionalized nucleolipid is accommodated into the liposome bilayer 
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3.2 AIM 
The aim of this work is the in vitro biological characterization of ToThyCholRu/DOTAP, a 
possible anticancer agent, obtained from the previously tested liposomes 
ToThyRu/DOTAP, by adding of cholesterol. The goal is thus improving the nanovectorial 
system by the inclusion of this steroid, that is well known as natural constituent of cell 
membranes and very important for the integrity of the lipid bilayer; it could ensure not 
only the stability of the liposomes, but also the biocompatibility and the interaction with 
cell membranes during the process of internalization. First, we evaluated the effect on the 
cellular viability both on cancer and healthy cells. Then, the cellular uptake by fluorescent 
microscope was estimated. Finally, evaluations on the identity of the cell damage caused 
were provided, by DNA fragmentation assay and the analysis of the cell morphology by 
light microscopy.            
 
3.3 MATERIALS AND METHODS 
3.3.1 Cell cultures 
Human WiDr epithelial colorectal adenocarcinoma cells, HeLa cervical adenocarcinoma 
cells, MCF-7 breast adenocarcinoma cells, and rat L6 skeletal muscle cells were purchased 
from ATCC (American Type Culture Collection, Manassas, Virginia, USA), while HaCaT 
keratinocytes were taken from CLS (Cell Lines Service GmbH, Eppelheim, Germany). 
MCF-7 and WiDr cells were grown in RPMI 1640 medium (Invitrogen, Paisley, UK), 
whereas HeLa, HaCaT and L6 cells were grown in DMEM (Invitrogen, Paisley, UK). 
Media were supplemented with 10% fetal bovine serum (FBS, Cambrex, Verviers, 
Belgium), L-glutamine (2 mM, Sigma, Milan, Italy), penicillin (100 units/ml, Sigma) and 
streptomycin (100 μg/ml, Sigma), according to ATCC recommendations. The cells were 
cultured in a humidified 5% carbon dioxide atmosphere at 37 °C.  
 
3.3.2 In vitro bioscreening 
For the in vitro bioscreening, the cells were treated for 48 h with a range of concentrations 
(10→1000 μM) of AziRu and ToThyCholRu complex lodged in DOTAP liposomes, as 
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well as with Ruthenium-free ToThyChol/DOTAP liposomes as negative control and with 
cisplatin (cDDP), like positive control for the cytotoxic effects. Cell viability was 
evaluated with the MTT assay and Trypan Blue Exclusion cell count, as described above 
(par. 2.3.2). 
3.3.3 Fluorescence microscopy and cellular uptake of liposomes 
A standardized protocol (par. 2.3.3) based on a rhodamine B fluorescent probe loaded into 
DOTAP/ToThyCholRu liposomes has been used to evaluate the uptake of 
ToThyCholRu/DOTAP in human MCF-7 cells and WiDr adenocarcinoma cells; this 
experiment was carried out at 100 µM concentration and at incubation times of 30 min, 1, 
3 and 6 h. 
3.3.4 Light Microscopy 
MCF-7, WiDr and HeLa cell lines were grown on standard sterile plastic 60 mm culture 
dishes by plating 5 x 10
5
 cells. After reaching the subconfluence, cells were incubated for 
48 h with 50 μM concentration of ToThyCholRu/DOTAP liposomes under the same 
experimental conditions described above. Finally, cells were observed by a contrast-phase 
light microscope (Labovert microscope, Leizt). Microphotographs at 200 × total 
magnification (20 × objective and 10 × eyepiece) were taken with a standard VCR camera 
(Nikon). 
3.3.5 DNA fragmentation assay 
MCF-7, WiDr and HeLa cell lines were grown on standard sterile plastic 60 mm culture 
dishes by plating 5 x 10
5
 cells. After 24 h of growth the cells were treated for 48 h with 
IC50 doses of ToThyCholRu/DOTAP liposomes, as well as with IC50 doses of cisplatin 
(cDDP) as positive control for in vitro induction of apoptosis. Then, the DNA was 
extracted and analyzed as previously described (2.3.6). 
3.3.6. Statistical Analysis 
All data were presented as mean ± SEM. The statistical analysis was performed using 
Graph-Pad Prism (Graph-Pad software Inc., San Diego, CA) and ANOVA test for multiple 
comparisons was performed followed by Bonferroni's test.  
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3.4. RESULTS 
[These data have been published: Vitiello G, Luchini A,
 D’Errico G, Santamaria R, 
Capuozzo A,
 
Irace C,
 
Montesarchio D,
 
Paduano L. Cationic Liposomes as Efficient 
Nanocarriers for the Drug Delivery of an Anticancer Cholesterol-based Ruthenium 
Complex. J. Mater. Chem. B 2015, 3:3011-3023] 
 
3.4.1 In vitro bioscreening for anticancer activity  
The cytotoxic effects of ToThyChol/DOTAP were investigated on a selected panel of 
cancer and healthy cells. The antiproliferative activity was evaluated through the 
estimation of a “cell survival index”, arising from the combination of cell viability with 
cell counting. Data concerning the previously investigated ToThyCholRu/POPC system 
[Simeone et al., 2012] are included for comparison. The results (Fig. 37 and Table 2) show 
that ToThyCholRu/DOTAP has an interesting bioactivity pattern characterized by selective 
cytotoxicity against highly proliferative malignant cells. In fact, different human 
adenocarcinoma cells, such as MCF-7, WiDr and HeLa, are susceptible to the 
antiproliferative effects of this nanovector, while no significant cytotoxicity has been 
detected on normal human HaCaT keratinocytes and rat L6 muscle cells. The poor activity 
of ToThyCholRu/DOTAP on normal cells could be explained by the Clark's hypothesis of 
the activation of ruthenium (III) complex only in the reducing environment of cancer cells 
[Schluga et al. 2006; Clarke et al, 1999; Clarke et al.,1980]. Taking into account that 
ruthenium is incorporated in 30% in moles in the DOTAP liposomes under investigation, 
concentration-effects curves related to the actual ruthenium content highlight the 
antiproliferative activity of the ToThyCholRu/DOTAP system. We can synthesize the 
antiproliferative results on cancer cells with the following order: ToThyCholRu/DOTAP ≥ 
cisplatin > ToThyCholRu/POPC > AziRu. Indeed in the changeover from 
ToThyCholRu/POPC to ToThyCholRu/DOTAP the potentiating factor (PF) values (Table 
2) for ruthenium vectorization respect to the precursor molecule AziRu in MCF-7 and 
WiDr cells increases from 4.3 and 3.1 to 23.5 and 22.4, respectively. Thus in MCF-7 cells, 
the most responsive cells in these in vitro models, the same antiproliferative effect of the 
precursor complex AziRu is achieved in the case of ToThyCholRu in POPC, with a metal 
concentration 6-fold lower, and in the case of ToThyCholRu in DOTAP, with a metal 
concentration 10-fold lower. ToThyCholRu/DOTAP is more potent than cisplatin against 
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two of the three cancer cell lines tested (approximately 1.7 and 1.4-fold more effective on 
MCF-7 cells and WiDr, respectively), while HeLa cells rest more responsive to cisplatin. 
In line with the data obtained for ToThyRu/POPC and ToThyRu/DOTAP, discussed in the 
previous chapter, the calculated IC50 for ToThyChol/DOTAP are significantly lower than 
those related to the same nucleolipidic ruthenium (III) complex lodged in neutral POPC 
liposomes. This means that, under identical in vitro experimental conditions, the use of 
cationic DOTAP liposomes as nanocarrier for ToThyCholRu enhances its anticancer 
activity. It is also interesting to confront the IC50 values obtained by the cell survival index 
of ToThyCholRu/DOTAP (Table 2) with those showed in the previous chapter for 
ToThyRu/DOTAP (Table 1). In fact, we can note an increment of the antiproliferative 
activity in the transition from cholesterol-free to cholesterol-including cationic liposomes, 
that is more important again if we take into account that the amount of ruthenium in these 
liposomes is not the same, but 50% and 30% in moles respectively. The corresponding IC50 
referring to the ruthenium concentration of ToThyCholRu/DOTAP and ToThyRu/DOTAP 
are 19±8 (PF 16) versus 13±2 (PF 23.5) on MCF-7 cells, 50±11 (PF 9) versus 23±8 (PF 
22.4) on WiDr cells. Therefore, the inclusion of cholesterol improves effectively the 
antiproliferative effect of the ruthenium-based nanovectors, allowing to reducing the quote 
of active principle vehiculated to obtain the same activity, and thus minimizing the 
possible onset of side effects. The observed antiproliferative effects of  
ToThyCholRu/DOTAP on tumor cells show that the amphiphilic nature of this 
nanoaggregate, do not perturb, but also helps, the metal-induced biological effects.  
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Fig.37. Cell survival index  for MCF-7, WiDr, and HeLa  cell lines following 48 h of 
incubation with the indicated concentration  of AziRu and of the ruthenium-containing 
ToThyCholRu/DOTAP and ToThyCholRu/POPC liposomes, cDDP as positive control for 
cytotoxicity, the ruthenium-free ToThyChol/POPC and ToThyChol/DOTAP liposomes as 
negative controls. and the corresponding concentration-effect curves by normalizing for 
the actual ruthenium amount contained within ToThyCholRu/DOTAP and 
ToThyCholRu/POPC liposomes (on the right). Data are expressed as percentage of 
untreated control cells and are reported as mean of five independent experiments ± SEM (n 
= 30). 
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Tab.2. 
 
IC50 values, reported as mean ± SEM(n = 30) of five independent experiments;in 
bold, the potentiating factor (P.F.), calculated as the ratio of IC50 values of 
ToThyCholRu/POPC and ToThyCholRu/DOTAP liposomes with respect to the IC50 of 
AziRu. 
 
              3.4.2. Cellular uptake  
The internalization and accumulation of the metal-based drugs into cancer cells is crucial 
for the therapeutic effect against tumors [Groessl et al., 2011]. In view of more detailed 
investigations on the interactions of the ruthenium-based nanovectors with the cells, we 
have analyzed their cellular internalization process. A standardized protocol based on a 
rhodamine B fluorescent probe loaded into DOTAP/ToThyCholRu liposomes has been 
used to evaluate their uptake in human carcinoma cells. In order to determine the 
relationship between the incubation times and the ToThyCholRu accumulation within the 
cells, the experiment was carried for 30 min, 1, 3 and 6 h on human MCF-7 breast and 
WiDr colorectal adenocarcinoma cells. In the microphotographs (fig. 38 and 39), the blue 
areas correspond to the cells nuclei specifically stained by DAPI, whereas the rhodamine 
(RHOD) associated fluorescence within cells is shown in green. Control experiments have 
been also performed by exposing the cells to the rhodamine B adduct alone, under the 
same in vitro experimental conditions used to evaluate the cellular uptake of ruthenium-
containing liposomes. Merged images arise by overlapping fluorophores emission 
emerging from the same cell monolayers. The cationic ToThyCholRu/DOTAP liposome 
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rapidly interacts with the cells allowing a massive cellular uptake, even after 30 min. The 
rhodamine-dependent fluorescence emission is widespread in the cells and merged images 
show a strong fluorescence accumulation. Interesting, it is possible to identify a different 
kinetics of action on MCF-7 and WiDr cells; in fact, at 30' of incubation, the accumulated 
fluorescence seems depend on a high quantity of ToThyCholRu/DOTAP already 
internalized by the MCF-7 cells, whereas the more diffuse fluorescence at the same time of 
incubation in WiDr cells is a signal of a more bland interaction, that nevertheless rapidly 
increase over time. These observations could be correlated with the data about the cell 
viability, according to which the MCF-7 cells are the more sensitive to the nanovector, 
suggesting that the selectivity between different types of cancer cells may depend also on 
the capacity of the liposomes to interact with the cell membranes. In a process of cell 
internalization that probably occurs via membrane fusion and/or by endocytosis, the 
presence of a cholesterol motif within the amphiphilic structure decorating the ruthenium 
complex in ToThyCholRu, could further improve the liposome fusion with the plasma 
membrane, thus promoting nanocarriers accumulation in the cells. In addition to the 
amphiphilic properties of ToThyCholRu complex, the liposome membranes formed by the 
cationic lipid DOTAP allow the onset of charge attraction that could play an important role 
in promoting close contact with the negatively charged target membrane [Xiong et al., 
2011].   
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Fig. 38.  Uptake of  Rhodamine-labeled ToThyCholRu/DOTAP liposomes by human 
MCF-7 breast adenocarcinoma cells incubated for 30 min, 1, 3 and 6 h. The blue-
fluorescent DAPI specifically stains the nuclei. The RHOD fluorescence was shown in 
green. In merged microphotographs (Merged), the two fluorescent patterns are overlapped. 
The shown images are representative of three independent experiments. 100× total 
magnification (10 × objective and a 10 × eyepiece). 
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Fig. 39. Uptake of  Rhodamine-labeled ToThyCholRu/DOTAP liposomes by human WiDr 
colorectal adenocarcinoma cells incubated for 30 min, 1, 3 and 6 h. The blue-fluorescent 
DAPI specifically stains the nuclei. The RHOD fluorescence was shown in green. In 
merged microphotographs (Merged), the two fluorescent patterns are overlapped. The 
shown images are representative of three independent experiments. 100× total 
magnification (10 × objective and a 10 × eyepiece). 
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3.4.3. Cellular morphological changes and DNA fragmentation  
To further support the relationship between cell viability and ruthenium-induced 
cytotoxicity, subconfluent cultures of MCF-7, WiDr and HeLa cells have been analyzed by 
phase-contrast light microscopy for monitoring the dynamic morphological changes that 
occur during cell death induced by the treatment. In fact, following the in vitro exposure to 
ToThyCholRu/DOTAP, the cell monolayers clearly appear perturbed in their 
morphological architecture. In particular, the microphotographs (Fig. 40) show that the 
reduction in cell viability by ruthenium-based nanocarriers is associated with well 
detectable cytotoxic effects and characteristic morphologic hallmarks of apoptosis, such as 
membrane blebs and cell shrinkage at the start of apoptosis, and the formation of balloon-
like structures, due to the loss of plasma membrane integrity, at the late state [Krysko, et 
al., 2008]. The rounding of the cells visibly increased after 48 h of incubation, with 
improvement of the surface blebbing and cell contraction. Since late events of apoptosis 
include nuclear pycnosis and DNA cleavage [Elmore., 2007], we also analyzed the DNA 
fragmentation by agarose gel electrophoresis. In Fig. 41 untreated cancer cells showed no 
detectable DNA fragmentation, whereas DNA extracted from cells after 48 h of incubation 
with IC50 doses of both ToThyCholRu/DOTAP and cDDP was extensively fragmented. 
Treatment of the cells with ToThyCholRu/DOTAP resulted in the appearance of the 
internucleosomal DNA laddering typical of cells undergoing apoptosis. As widely 
described in the previous chapter, MCF-7 cells not express the CASP-3 [Jänicke, 1998], 
even if the DNA fragmentation is similar to that induced in vitro by IC50 doses of cDDP, 
likely via caspase-3 activation [Okamura et al., 2004]. We can thus suppose that this 
fragmentation may correlate with the activation of different effector caspases, such as 
caspase-6 or -7 [Liang et al., 2001]. Although the implication of different processes of cell 
death cannot be excluded, these finding provide evidence of an apoptosis-inducing activity. 
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Fig. 40. Representative microphotographs at a 200 × magnification (20 × objective and a 
10 × eyepiece) by phase-contrast light microscopy of MCF-7 (panel A), WiDr (panel B) 
and HeLa (panel C) cell lines untreated (control cells, left column) or treated for 48 h with 
50 µMToThyCholRu/DOTAP (right column), showing the morphological changes of cells 
and the cytotoxic effects on cellular monolayers.The shown images are representative of 
three independent experiments. 
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Fig. 41. DNA fragmentation assay on MCF-7, WiDr and HeLa cells, treated or not (Ctrl) 
for 48 h with IC50 doses (13, 23, and 34 µM, respectively) of ToThyCholRu/DOTAP (Ru) 
or with IC50 doses (22, 32, and 12 µM, respectively) of cDDPas positive control. Lane M 
corresponds to molecular weight markers. The agarose gel is representative of three 
independent experiments. 
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3.5. CONCLUSIONS 
 
In order to develop stable and long-life anticancer ruthenium agents, the co-aggregation 
with biocompatible lipids represents an innovative strategy for their in vivo delivery. In 
particular, we tested the cholesterol-containing ruthenium complex, named ToThyCholRu, 
which is negatively charged and accommodated into the liposome bilayers formed by the 
cationic lipid DOTAP. Interestingly, ToThyCholRu/DOTAP liposome is stable for several 
months, ensuring the complete integrity of the active ruthenium complex in physiological 
environment. Moreover, the antiproliferative activity of ToThyCholRu/DOTAP is 
comparable to that of cisplatin, whereas this nanovector is less toxic on normal cells. Since 
most anticancer drugs lack of cancer specificity and cause side effects on normal tissues, 
ruthenium complexes may provide a more safe and at the same time effective alternative to 
common chemotherapeutic agents. In addition, in the transition from ToThyCholRu/POPC, 
as well as from ToThyRu/DOTAP, to ToThyCholRu/DOTAP considerable progresses 
have been achieved in term of drug delivery, due to the better interaction with the cells. 
The efficacy of ruthenium is thus improved by the cationic charge of the surface of 
liposome bilayer, but also specifically by the cholesterol inclusion, as direct consequence 
of an increased cellular uptake. In confirmation of these results, an efficient and fast 
liposomes accumulation in the cells has been detected. Thus, in addition to the important 
role played by the positive superficial charge of the aggregates, the steroid moiety of the 
nucleolipid complex inserted in the acyl chain region, could play an important role in the 
improving the nanovector, for its ability to regulate the physico-chemical properties of 
lipid bilayers, to stabilize liposomes and to modulate membrane trafficking by enhancing 
the liposome fusion with the plasma membrane. In conclusion, this study shows that the 
co-aggregation of nucleolipid ruthenium complexes with the cationic lipid DOTAP has a 
great potential for developing new ruthenium-based anticancer drug candidates. 
Particularly, ToThyCholRu/DOTAP has exhibited a remarkable cytotoxicity and 
selectivity toward cancer cells. These findings suggest a relevant specificity in the 
molecular interactions of ruthenium, in its active form, with the biological targets. Thus, 
further studies will be done in vitro and in vivo, in order to investigate the structure–
activity relationship and the physiological implications of their antitumor activity. 
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4.1 INTRODUCTION 
4.1.1 Long-time circulation strategy for the new generation of liposomes   
Many researches are focused on improving the drug delivery activity of the nanovectors, 
increasing their drug loading, targeting capability, and stability in physiological conditions, 
minimizing in parallel the toxic effects [Bozzuto and Molinari, 2015]. A common approach 
to obtain efficient drug delivery systems is based on the introduction of polyethylene 
glycol (PEG) into liposomal formulations [Vertut-Doï et al., 1996]. This hydrophilic 
polymer having a flexible chain that occupies the space immediately adjacent to the 
liposome surface, tends to exclude other macromolecules from this space, such as the 
serum proteins, and partially covers the aggregates in the blood, bypassing the control of 
the immune system, thus preventing opsonization and the subsequent macrophage uptake 
[Immordino et al., 2006]. The result of the use of PEG-vescicles is an increase of the 
liposomes lifetime under physiological conditions, which makes these systems suitable for 
in vivo applications. However, recent studies have shown several side effects associated 
with the use of PEGylated systems, including hypersensitivity, formation of toxic products, 
and accelerated blood clearance after several injections or, in other cases, phenomena of 
accumulation in the body [Knop et al., 2010]. Consequently, there is a growing interest on 
the research of alternative substances which, incorporated into liposomes as additives, are 
able to prolong the life span of the drug, but at the same time making stealth the system 
and showing less side effects.      
 
4.1.2 The LOS inclusion into the liposome 
Aiming at enhancing the efficacy of the second generation of drug delivery systems, we 
tested a new formulation functionalized with the lipooligosaccharide (LOS) derived from 
bacteria wall, instead of classical PEG decoration. LOS-liposomes can be produced in 
large amount by bacterial fermentation thus avoiding long and complicated synthetic 
procedures, and are bifunctional molecules with a carbohydrate epitope at one side, and the 
Lipid A moiety at the other, useful to easily incorporate the molecule in the liposome [De 
Castro et al., 2008; D'Errico et al., 2010; D'Errico et al., 2009]. The LOS and the 
lipopolysaccharide (LPS) are the principal components of the outer membrane of Gram-
negative bacteria, responsible for the integrity and the stability of the bacterial architecture. 
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LPS consists of the lipid A, the outer and the inner core, and the O-antigen. The O-antigen 
is exposed on the bacterial surface, allowing the recognition by specific antibody. In this 
context, the usage of the LOS, lacking of the O-antigen, avoids the acquired immunity. On 
the other hand, the lipid A moiety, consisting of a glucosamine disaccharide decorated with 
several long chain fatty acids and two phosphate units is known as a PAMP (Pathogen 
Associated Molecular Pattern) agent and recognized by receptors of the innate immune 
system that in response to this binding activate the inflammation process [Molinaro et al.,  
2015]. However, depending on the bacterial origin, the number and length of the fatty 
acids of the Lipid A as well as of the kind of sugars forming the core can differ, and can 
give diverse inflammatory properties. Thus, an appropiate choice of the bacteria species 
from which the LOS are extracted, joined to a variety of possible chemical modifications 
to made on the Lipid A structure can significantly reduce, and even eradicate, the response 
of the immune system. In our case, we tested the LOS extracted by Rhizobium rubi 
(Fig.42), in which the de-O-acylation of the lipid A was introduced in order to ensure the 
liposome stability and to avoid the recognition by the immune system, so that a prolonged 
circulation in blood can be predict. In addition, this specific LOS presents interesting 
features: literature data indicate that it has poor inflammatory properties [Vandenplas ML 
et al., 2002] and it presents within the core region the Lewis B oligosaccharide, a human 
epitope which should give stealth properties to the liposome, and thus prolonged life span 
by molecular mimicry of host structures, similarly to the strategy exploited by 
Helicobacter pylori during the infective process [Moran AP,2008].  
 
Fig.42. Molecular structure of de-LOS from Rhizobium rubi. 
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This liposome has been prepared by co-formulating the nucleolipid-based Ru (III) complex 
ToThyRu with the zwitterionic lipid POPC containing de-O-acylated LOS (de-LOS) in the 
proportion 10:80:5 (Fig. 43). A detailed physico-chemical characterization has been carried 
out by means of different experimental techniques, including Dynamic Light Scattering 
(DLS), Small Angle Neutron Scattering (SANS), and Electron Paramagnetic Resonance 
(EPR) and has confirmed that insertion of de-LOS in the formulation leads to stable multi-
layered aggregates. 
 
Fig.43. Simplified representation of the de-LOS-liposome 
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4.2 AIM  
We tested a neutral liposome functionalized with the lipooligosaccharide extracted from 
the bacteria R. rubi, in order to mimic the bacterial cell wall, and at the same time, by ad 
hoc modification (de-Oacylation), avoiding the activation of inflammatory response. To 
better elucidate the role played by de-O-acylated LOS in the liposome activity, biological 
investigations were performed, in order to evaluate the effect of ToThyRu/POPC/de-LOS 
on three different cellular models:  
1) The human breast adenocarcinoma cell line MCF-7, to assess its anticancer efficacy   
2) The normal cell line of human keratinocytes HaCaT, to investigate the cytotoxic 
effect  
3) The murine monocyte/macrophages J774 to predict the immune innate response 
and thus verify their capacity to be a stealth system  
Thus the first goal was to verify the effective biocompatibility of de-LOS-containing 
nanovectors, ensuring the theoretical safety of these nanoaggregates towards biostructures, 
as important prerequisite for their possible in vivo use, as well as the efficacy of 
ToThyRu/de-LOS on the cancer cells. Then, to investigate the cellular uptake, experiments 
of fluorescence microscopy were performed. Finally the absence of  immune responses 
was ascertained by determination of nitric oxide production and Western Blot analysis of 
the inducible form of nitric oxide synthase (iNOS).   
 
4.3. MATERIALS AND METHODS 
4.3.1. Cell cultures  
Experiments were carried out on human HaCaT keratinocytes cells (CLS service), human 
MCF-7 breast adenocarcinoma cells and murine J774 monocyte/macrophage cell line 
(ATCC). HaCaT and J774 cells were grown in Dulbecco’s modified Eagle’s medium 
(DMEM, Invitrogen, Paisley, UK) containing high glucose (4.5 g/l), while MCF-7 cells 
were grown in RPMI 1640 medium (Invitrogen, Paisley, UK). Media were supplemented 
with 10% fetal bovine serum (FBS, Cambrex, Verviers, Belgium), L-glutamine (2 mM, 
Sigma), penicillin (100 units/ml, Sigma) and streptomycin (100 mg/ml, Sigma). All the 
cells were cultured in a humidified 5% carbon dioxide atmosphere at 37 °C. 
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4.3.2. In vitro bioscreens for cell survival 
Each cell line was treated with a range of concentrations (10→100 µM) of AziRu and 
ToThyRu lodged in POPC liposomes functionalized or not with de-LOS (ToThyRu/POPC 
and ToThyRu/POPC/de-LOS, respectively). Using the same experimental procedure, cell 
cultures were also incubated with the ruthenium-free ToThy/POPC and ToThy/POPC/de-
LOS liposomes as negative controls, as well as with cisplatin (cDDP) like positive control 
for cytotoxic effects. The bioactivity was investigated by the cell viability evaluation and 
the cell counting, as described above (par. 2.3.2). 
 
4.3.3. Cellular uptake by fluorescence microscopy 
The cells were treated for 3 and 6 h with 100 µM of de-LOS liposomes containing a 
fluorescent rhodamine B derivative. The procedure for the fluorescent microscopy 
experiment is illustrated in the chapter 2 (par. 2.3.3). 
 
4.3.4. Macrophage activation and nitric oxide production 
J774 monocyte/macrophage cells were plated in 96-well cell culture microplate at density 
of 10
4
 cells/well and allowed to adhere for 24 h at 37 °C. The medium was replaced with 
fresh medium and cells were treated for 24 h with a range of concentrations (10-100 µM) 
of POPC/de-LOS liposomes and of ToThyRu/POPC/de-LOS, as well as with 1 and 10 
μg/ml of LPS from Salmonella typhosa used as positive control for macrophage activation 
and nitric oxide production. In vitro integrated nitric oxide production was estimated by 
determining the concentration of nitrite and nitrate end-products. The measurement of 
nitrate/nitrite concentration or of total nitrate and nitrite concentration (NOx) is routinely 
used as an index of NO production. In particular, to evaluate the total nitrite release in the 
culture medium, 100 μl of Griess reagent (0.1% naphthylethylenediamide dihydrochloride 
in H2O and 1% sulphanilamide in 5% concentrated H2PO4) were added to 100 μl medium 
of each sample. Nitrite concentration was calculated by comparison of OD550 samples with 
sodium nitrite standard solution OD550. The optical density at 550 nm (OD550) was 
measured using a microplate reader (iMark microplate reader, Bio-Rad). 
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4.3.5. Western blot analysis of iNOS expression 
After 24 h of treatment with (10-100 µM) of ToThy/POPC-de-LOS and ToThyRu/POPC-
de-LOS, J774 cells were collected, washed, and resuspended in the buffer containing 10 
mM Tris-HCl, pH 7.6, 50 mM NaCl, 1% Triton X-100, and protease inhibitor cocktail 
(Roche Diagnostics, Mannheim, Germany). Cell debris were pelleted by centrifugation at 
4 °C for 20 min at 14,000 × g, and protein concentration of cell lysate was determined by 
the Bio-Rad protein assay (Bio-Rad). 50 μg of proteins were separated on a 8% SDS-
polyacrylamide gel and electrotransferred onto a nitrocellulose membrane (Amersham 
Biosciences) using a Bio-Rad Transblot (Bio-Rad). Immunodetection was performed using 
a primary rabbit antibody iNOS (Calbiochem, San Diego, CA) with appropriate secondary 
antibody and detected by chemiluminescence. Tubulin antibody was used to normalize the 
results. 
 
4.3.6. Statistical Analysis 
All data were presented as mean ± SEM. The statistical analysis was performed using 
Graph-Pad Prism (Graph-Pad software Inc., San Diego, CA) and ANOVA test for multiple 
comparisons was performed followed by Bonferroni's test. 
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4.4. RESULTS 
4.4.1. Anticancer activity  
As showed in figure 44A, in vitro bioscreens were performed in order to explore the 
bioactivity of zwitterionic POPC liposomes incorporating both ToThyRu and de-LOS. 
Notably, the related IC50 values (Table 3) for the LOS derivative ruthenium-free are higher 
than 10
3
 µM for all the examined cell populations, suggestive of the absence of 
antiproliferative effects and of virtually null cytotoxicity; this result make possible the 
potential use of this nanovector as biocompatible system for the drug delivery. On the 
other hand, ToThyRu/POPC/de-LOS has shown cytotoxicity against highly proliferative 
malignant cells. Human MCF-7 adenocarcinoma cells undergo remarkable antiproliferative 
effects following incubation with POPC liposomes incorporating both the ruthenium-based 
nucleolipidic complex ToThyRu and de-LOS. Taking into account that the actual 
ruthenium concentration in this nanosystem is only the 10 %, these results indicate an in 
vitro cytotoxic activity similar to that of cisplatin, but at the same time the nanovectorial 
system can significantly contribute to reduce the side effects associated with 
chemotherapy. Aiming at investigating the cellular internalization processes, a 
standardized protocol, based on a rhodamine B fluorescent probe loaded into 
ToThyRu/POPC/de-LOS liposomes at 2% mol, was used.
 
The microphotographs (Fig. 
44B) show a strong fluorescence accumulation following the treatment with the liposomes 
in the cancer cells, confirming the ability of this system to act as nanocarrier for ToThyRu. 
 
4.4.2. Effect on healthy cells 
Very interestingly, no significant cytotoxicity has been detected on the human HaCaT 
keratinocytes treated with ToThyRu/POPC/de-LOS, showing approximately the same cell 
survival index of the liposomes ruthenium-free (Fig. 45A and Table 3). On the other hand, 
its uptake in these cells should not be overlooked. In fact, the microphotographs in figure 
45B demonstrate that a discrete quote of fluorescence is accumulated inside the cells, in a 
similar way to that showed for the cancer cellular uptake, suggesting that the nanovector, 
by mechanism of adsorption and/or fusion with the cell membranes, is internalized in the 
keratinocytes. Therefore, the comparison between the celluar uptake and the lack of 
bioactivity, gives important information about the in vitro pharmacodynamics of the 
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ruthenium complex; in fact, although delivered in the normal cells as in the cancer cells, it 
doesn't explicate the same cytotoxic effect. This result provides further evidences of an in 
situ activation mechanism for Ru-complexes, specifically operative in the cancer cells 
microenvironment, in accordance with the assumption that Ru (II) complexes are generally 
more reactive than Ru (III) complexes, which substantially act as inactive pro-drug, and 
that exclusively the chemically reducing environment of cancerous cells would allow the 
ruthenium reduction  [Schluga et al. 2006; Clarke et al, 1999; Clarke et al.,1980].  
However, the evaluation of ruthenium-based complexes effects on healthy control cell 
cultures needs further study, focusing mainly on the understanding the molecular basis of 
this different response to the drug.  
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Fig. 44. MCF-7 cell lines. A. Cell survival index following 48 h of incubation with the 
indicated concentration of AziRu, Cisplatin (cDDP), the ruthenium-free (ToThy/POPC, 
ToThy/POPC/de-LOS) and ruthenium-containing (ToThyRu/POPC, ToThyRu/POPC/de-
LOS) liposomes. On the right, the corresponding concentration-effect curves by 
normalizing for the actual ruthenium amount (in logarithmic scale) contained within the 
liposomes. B. Uptake of the Rhodamine B-labeled ToThyRu/POPC/de-LOS liposomes 
(shown in green) after 3 and 6 h of treatment. The blue fluorescence of DAPI specifically 
stains the nuclei. In merged microphotographs the two fluorescent patterns are overlapped. 
The images are representative of three independent experiments.  
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Fig. 45. HaCaT cell lines. A. Cell survival index following 48 h of incubation with the 
indicated concentration of AziRu, Cisplatin (cDDP), the ruthenium-free (ToThy/POPC, 
ToThy/POPC/de-LOS) and ruthenium-containing (ToThyRu/POPC, ToThyRu/POPC/de-
LOS) liposomes. On the right, the corresponding concentration-effect curves by 
normalizing for the actual ruthenium amount (in logarithmic scale) contained within the 
liposomes. B. Uptake of the Rhodamine B-labeled ToThyRu/POPC/de-LOS liposomes 
(shown in green) after 3 and 6 h of treatment. The blue fluorescence of DAPI specifically 
stains the nuclei. In merged microphotographs the two fluorescent patterns are overlapped. 
The images are representative of three independent experiments. 
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4.4.3. Macrophage response to de-LOS liposomes  
Macrophages, involved at all stages of immune response, are a central component of the 
host defence system and the detection of nitric oxide (NO∙) produced by activated 
phagocytes in vitro represents a good method to estimate the antigenic ability of 
functionalized liposomes [Bogdan et al., 2015]. In the biological environment, the nitric 
oxide is rapidly oxidized to nitrite and/or nitrate by oxygen, so that nitric oxide production 
can be estimated by determining the concentration of nitrite or nitrate end-products [Pacher 
et al., 2007]. Due to their multitasking aptitude, the murine J774 macrophage-like cell lines 
are a well-established in vitro model system in cell biology and immunology [Lam et al., 
2009]. As shown in Figure 46A, the stimulation of J774 macrophages by bacterial 
lipopolysaccharide (LPS from Salmonella typhosa, 1 and 10 μg/ml for 24 h) visibly results 
in a marked increase of NO production (6.5 ± 1.3 and 9.7 ± 1.03 µM/10
4
 cells, 
respectively), compared with control cultures (0.02 ± 0.3 µM/10
4
 cells). In the same 
experimental conditions, in vitro macrophages treatment with POPC/de-LOS liposomes, 
and with ToThyRu/POPC/de-LOS liposomes does not induce significant NO production at 
all the tested concentrations. Activated murine macrophages produce large amounts of NO 
from L-arginine via induction of the inducible form of nitric oxide synthase (iNOS), a 
highly regulated enzyme [Hillaireau et al., 2009]. According to nitrite determination, 
Western blot analysis of iNOS (Fig. 46B) shows that LPS stimulation significantly induces 
iNOS expression, whereas no protein induction following macrophages exposure to LOS-
decorated liposomes is detected. It is interesting to highlight that the experiments on the 
cellular uptake, showed in Figure 47B, reveal a low level of internalized de-LOS-decorated 
liposomes in this cell line, although no evidence of macrophages activation response 
effects were observed. Therefore, it is likely that de-LOS-containing liposomes interact 
with macrophages by a passive process, such as cell fusion and/or adsorption as well as for 
the other cell lines, without stimulating the surface receptors involved in macrophages 
activation. This scenario does not change in the presence of the liposome-entrapped 
ruthenium complex. The cell survival index (Fig. 47A) demonstrates that this "passive 
uptake" doesn't lead to a cytotoxic effect, according with the absence of significant 
bioactivity by Ru (III) complexes in the keranotinocytes and thus remarking the possibility 
of the ruthenium activation specifically in cancer cells. Therefore, the tested 
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ToThyRu/POPC/de-LOS does not interfere with in vitro macrophages activation as well as 
with the cell viability.  
 
 
Fig.46. (A) Effect of the indicated concentrations of ToThy/POPC/de-LOS and of 
ToThyRu/POPC/de-LOS functionalized liposomes on nitric oxide production in J774 cells 
evaluated by means of nitrite determination following 24 h of exposition to liposomes. 
J774 cells were stimulated for 24 h with LPS (1 and 10 μg/ml) as positive controls. Data 
are expressed as µM of nitrite/million viable cells and are plotted in a bar graph as mean ± 
SEM (n = 15) of three independent experiments. *** p<0.001 vs unstimulated 
macrophages. (B) Effect of the indicated concentrations of ToThy/POPC/de-LOS and of 
ToThyRu/POPC/de-LOS functionalized liposomes on iNOS protein expression in J774 
macrophages evaluated by Western blot analysis. Data normalization was provided by 
LPS-stimulation (1 and 10 μg/ml for 24 h) and tubulin levels. 
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Fig. 47. J774 cell lines. A. Cell survival index following 48 h of incubation with the 
indicated concentration of AziRu, Cisplatin (cDDP), the ruthenium-free (ToThy/POPC, 
ToThy/POPC/de-LOS) and ruthenium-containing (ToThyRu/POPC, ToThyRu/POPC/de-
LOS) liposomes. On the right, the corresponding concentration-effect curves by 
normalizing for the actual ruthenium amount (in logarithmic scale) contained within the 
liposomes. B. Uptake of the Rhodamine B-labeled ToThyRu/POPC/de-LOS liposomes 
(shown in green) after 3 and 6 h of treatment. The blue fluorescence of DAPI specifically 
stains the nuclei. In merged microphotographs the two fluorescent patterns are overlapped. 
The images are representative of three independent experiments.  
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4.5. CONCLUSIONS 
In vitro bioscreenings to test the effect of ruthenium-based de-LOS liposome, have shown 
its selective cytotoxicity against human adenocarcinoma cells as well as extremely low 
toxicity for healthy cells. Also, the induction of cell stress in monocytes/macrophages and 
the subsequent analysis of NO production revealed the absence of significant NO 
production for both ToThyRu/POPC/de-LOS and ToThy/POPC/de-LOS formulations, 
indicating that no in vitro immune response is activated by this treatment, despite a cellular 
uptake process.  
Thus, we have demonstrated that the combination of the anticancer agent ToThyRu with a 
mixture of POPC and de-LOS lead to a liposomal formulation provided with: 
i) marked and selective anticancer activity, due to the presence of a properly 
functionalized amphiphilic Ru(III) complex 
ii) affinity for the human lipid cell membrane, due to the POPC self-assembly 
iii) no immune system stimulation, due to the capacity to act as a stealth system  
Taken together, these results demonstrate that, in the development of efficient nanocarriers 
for drug delivery, the here described supramolecular system, is a functional and 
biocompatible nanovector, efficient in the transport of an amphiphilic anticancer Ru(III) 
complex, but in principle useful for the in vivo delivery of a large variety of lipophilic 
drugs, that could enhance their life span in the blood. 
 
Table 3. Summary table of all the IC50 values (μM) arising from the cell survival index  of 
MCF-7, HaCaT and J774 cells, following 48 h-incubation of treatments. The effective 
metal concentrations within the ruthenium-containing aggregates were considered. 
 
IC50 
values are reported as mean ± SEM (n = 30) of five independent experiments. 
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5. RDCs and ODCs: the role of 
epigenetic changes in their  
mechanism of action 
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5.1. INTRODUCTION 
5.1.1. Ruthenium derived compounds (RDCs): state of the art  
RDC constitutes a family of cycloruthenated compounds, of which RDC11 
([ruthenium[phenanthroline][κ-C,N-[2-phenyl-pyridine][NCMe]2]PF6) is one of the best 
exponents, proving to be a good alternative to platinum compounds (Fig.48). In fact, it 
showed high antiproliferative effect (IC50 between 1-5µM) on multiple cancer cell lines, 
including also cells and human primary ovarian tumors that are resistant to Cisplatin 
[Gaiddon et al., 2005]. It inhibits also the growth of various tumors implanted in mice, 
including mouse syngeneic models (melanoma, lung cancer) and human xenografted 
models (glioma and ovarian cancer). In addition, unlike platinum compounds, RDCs do 
not cause severe side effects to the liver, kidneys, the neuronal sensory system or blood 
cells [Meng et al., 2009]. RDCs accumulate in nucleus, endoplasmic reticulum and 
mitochondria. Studies using drugs that block the active transport or various types of 
carriers indicate that a portion of RDCs enter the cells through an active mechanisms, in a 
concentration-dependent way and using several types of transporters [Klajner et al., 2014]. 
However, each component of RDC family showed a specific cytotoxic profile and different 
mechanism of action, suggesting that changes on the ligands in their structure modify their 
anticancer spectra of activity, because of different redox potential and ability to interact 
with DNA and other different macromolecules [Bergamo et al., 2012]. In the case of 
RDC11, only a bland interaction with DNA was found [Klajner et al., 2010], indicating 
that alternative targets are involved in their anti-tumor activity. Interestingly, RDC11 
induces p53-independent apoptosis [Gaiddon et al., 2005] but exerts its cytotoxicity 
through Endoplasmic Reticulum (ER) stress pathways. In particular, previous studies 
showed the activation of some gene-keys in the ER stress, like Bip, XBP1, PDI, and CHOP 
[Meng et al., 2009]. Activation of the transcription factor CHOP leads to the expression of 
several target genes, among which also the pro-apoptotic gene CHAC1 (Fig.49). However, 
both pathways, p53-independent apoptosis and ER stress, could not enough to explain all 
the biological effects of RDC11. Finally, structure-activity studies have indicated that 
RDCs’ cytotoxicity is at least partially associated with their redox potential and the 
production of reactive oxygen species [Vidimar et al., 2012]. 
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Fig. 48. Chemical structure of RDC11 
 
 
 
Bergamo et al., Journal of Inorganic Biochemistry, 2012 106:90–99 
Fig. 49. Proposed hypothesis on the mode of action of RDC11 on cancer cells. 
Abbreviations: ATF6 = Activating Transcription Factor 6; BiP: = binding immunoglobulin 
protein; BIM: = BH-3 (Bcl-2 homology domain-3) only protein; CHAC1 = cation transport 
regulator-like protein 1; CHOP = C/EBP homologous protein; RE = Response Element; 
TAp73 = transactivating p73; Trb3 = mammalian homolog of Drosophila tribbles; 
XBP1 = X-box binding protein 1. 
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5.1.2 Osmium derived compounds (ODCs) 
Recently, on the model of RDCs, a library of Cyclometalated Osmium (II) compounds 
were designed [Ryabov et al., 2003; Boff et al., 2013]. In figure 50, the structure of some 
of these ODC compounds of particular interest are reported; i) ODC2 that has the structure 
identical of RDC11 (the only difference is the metal change) serves as a model along with 
RDC11 at addressing the role of the metal in the cytotoxic activity; ii) ODC16 and ODC20 
that present a particular high cytotoxicity on the 60 cancer cell line of the National Cancer 
Institute and represent the second generation of ODC distinguished by having tri-dentate 
ligands, that could significantly change the scenario of interaction with macromolecules 
and cellular targets, as well as their uptake. ODCs have shown good in vitro cytotoxic 
profile, also in a cellular line of glioblastoma [Boff et al., 2013], that represents nowadays 
one of the most refractory tumors [Theeler et al., 2015]. As in the case of the 
cycloruthenate derivatives, these compounds showed a different activity in relation to the 
structure and the relative redox potential; in particular, it seems that the compounds which 
are more reactive to substitution reactions of a ligand, are less cytotoxic, suggesting that 
the most probable active species are those in which the coordination area of the metal is 
not modified before entering in the cells [Boff et al., 2013]. However, at the present there 
is no information about ODCs mechanism of action, even if the importance of their redox 
potential suggests that the mechanism involved in the tumor cell death could be, as 
reported for RDCs [Vidimar et al., 2012], a strong modification of the cellular metabolism, 
trough several interaction with different oxido-reductase enzymes.  
 
Fig. 50 Structure of some compounds of the ODC series (ODC2, ODC16, ODC20) 
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5.1.3. Epigenetic role in the mechanism of action of metal-based compounds 
Since there is a lack in the comprehension of the metal-based complexes’ mechanism of 
action, many efforts have been done in attempting to identify possible direct targets. In 
fact, several of these compounds, among which also RDC11, are not as good as platinum 
drugs to form stable DNA adducts [Klajner et al., 2010]. Nevertheless, they showed high 
cytotoxicity, suggesting the possibility of other targets as key players in the 
implementation of their antiproliferative effects. Also, the evaluation of the naked DNA 
binding "in vitro" would exclude all the physiological implications, like the ligand-
exchange kinetics and the binding with other molecules, as well as the interactions with the 
protein forming the chromatin, such as the histones [Davey GE and CA., 2008]. For 
example, the ruthenium containing drug RAPTA-C has been shown to interact with 
nucleosome core particle (NCP) by making adducts with the histones [Wu et al., 2011]. 
Interesting, it was found that RAPTA-C is more able to form adducts with histones than 
with the naked DNA, unlike another ruthenium-cymene compound, RAED-C, for which 
the binding balance is shifted toward the DNA, proving how the ligand substitutions are 
crucial for the ruthenium compounds interactions [Adhireksan et al., 2014]. Moreover, the 
ruthenium complex KP1019 showed a specific binding to the histone H3 [Singh et al., 
2014], that would evict histones from chromatin and provoke its destabilization. These 
events could finally promote a secondary binding with the DNA, making it more 
accessible, as hypothesized for oxaliplatin [Soori, 2015]. H3 is the unique histone that 
contains one or two cysteine (Cys) residues, highly conserved in the evolution; this 
aminoacid containing sulphydryl group, could make H3 as a "sensor" of redox state, very 
susceptible to oxidation [Garrard et al., 1977; Wood et al., 2006]. In the contest of metal-
based agents having different redox potentials and that explicate their mechanism of action 
partially by ROS production, H3 could represent the weakest link of chromatin, leading to 
chromatin disorganization.   
The possibility of ruthenium binding with histones is also supported by the identification 
of their specific sequences that can bind transition metals (Fig.51), such as Ni(II), Cu(II), 
Zn(II), Co(II). These sequences are the "C-tails" of H2A and H2B [Bal et al., 2000; Nunes 
 
et al., 2010], probably followed by their hydrolysis [Bal et al., 2000], the "N-Tail" of H4 
[Midorikawa et al., 2005; Zoroddu et al., 2010] in which the sites of acetylation are 
clustered, and in the cys-including motif of the H3 core [Bal et al., 1995].  
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Fig. 51. H2A.1, H2B.1A, H3.1, H4 sequences, in which the putative metal binding sites 
are highlighted. For H2A.1, the more probable point of hydrolysis subsequent to the 
binding is signed.  
As widely described above (par. 1.1.3.2.), the role of epigenetic changes in drug response 
is often attributed to their post-translational modifications, whose the most known are 
methylation, phosphorylation and acetylation [Kouzarides, 2007]. Also, the use of HDAC 
inhibitor has a synergic effect with platinum chemotherapy [Zhang et al., 2015] and can 
overcome the chemoresistance [Kumar et al., 2015]. All together, these evidences provide 
convincing considerations about the implication of the complex epigenetic machinery in 
the transition metals mechanism of action.  
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5.2 AIM 
While it is well established that the principal mechanism of platinum compounds is the 
DNA damage due to its direct binding and subsequent activation of apoptosis [Siddik, 
2003], it's not yet clear the activity of the complexes based on other transition metals. 
Some evidences showed a bland binding of RDC11 with DNA, which is not enough to 
explain its antiproliferative effects in vitro and in vivo, also higher than cisplatin. 
Moreover, the chromatin binding could involve not only the DNA, but also the protein 
components, such as the histones, that are very important for the chromatin organization 
and for the regulation of gene expression [Zhang et al., 2015]. Also, histones epigenetic 
modifications have proved essential for the mechanism of action of some anticancer drugs. 
In view of giving new information about the mode of action of metal-based compounds, 
our objective is to elucidate the role of histones as possible targets, and more in general of 
the epigenetic changes involved in their activity. In particular, this study is focused on the 
evaluation of:  
i) early DNA damage  
ii) direct interaction with histones 
iii) changes in histones expression and/or in their localization, due to the direct binding or 
to secondary processes subsequent i.e. to the oxidative stress  
iv) histones post-translational modifications  
 
Thus, Comet Assay was performed to analyze the DNA breaks, while electrophoresis of 
the purified histones treated with the compounds was carried out to see the difference on 
the migration of the monomers and their multiples, as well as to detect the presence of 
fragments. Western blot analysis were performed to investigate the histones expression and 
H3 acetylation, as well as to evaluate their different localization by means of two kinds of 
protein extraction buffer (NP-40, RIPA). Also, the analysis of caspase-3 activated 
fragments were conducted in order to considerate the results in the light of apoptotic cell 
levels. In addition, to correlate the data with the oxidative stress induced by the metal 
compounds, some experiments were carried out using the pre-treatment with the 
antioxidant agent N-acetylcystein. 
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5.3 MATERIALS AND METHODS 
5.3.1 Cell viability 
The antiproliferative effects of metal-based compounds were investigated by MTT assay 
on two cancer cell lines: the colorectal carcinoma HCT116 and gastric adenocarcinoma 
MKN45 cells. The cells were washed with PBS buffer solution (Sigma), collected by 
trypsine (Sigma) and then inoculated in a 96-microwell culture plates at density of 10
4
 
cells/well. Cells were allowed to grow for 24 h, then the medium was replaced with fresh 
medium and cells were treated for further 48 h with a range of concentrations (0.25→50 
μM) of cisplatin, oxaliplatin, RDC11, ODC2, ODC16 and ODC20. The MTT assay was 
performed as described above (par. 2.3.2) and the absorbance was monitored at 560 nm by 
using TriStar² LB 942 Multimode Microplate reader (Berthold Technologies GmbH & Co. 
KG Bad Wildbad, Germany). The calculation of the concentration required to inhibit the 
cell viability by 50% and 75% (IC50 and IC75) is based on plots of data carried (eight points 
per concentration, repeated three times). IC50 and IC75 values were obtained using a dose-
response curve by nonlinear regression using a curve fitting program, GraphPad Prism 5.0, 
and are expressed as mean ± SEM. 
 
5.3.2. Comet Assay 
The comet assay is a simple way for detecting DNA breaks. Cells are embedded in 
agarose, lysed, and subjected to electrophoresis; DNA containing breaks is attracted to the 
anode, forming a comet like image when viewed by fluorescence microscopy. Briefly, 
HCT116 cells were plated in 6 well plates (300.000 cells/well) one day before exposure. 
Semi-confluent cultures were exposed for 1 h with 10 and 25 µM of metal-based 
compounds. To detect the role of the oxidative stress inducted by metal-based compounds 
in the DNA damage, cells were pre-treated with 2 mM solution of the antioxidant N-
acetylcysteine (NAC) for 30 min. Hydrogen peroxide (H2O2) at 1 mM of concentration for 
10 minutes, is used as positive control of the oxidative DNA damage. The Comet assay 
was performed under neutral conditions [Boutet-Robinet et al., 2013]. Briefly, the cells 
were collected in 1x PBS and 500 µL of each sample is mixed with 500 µL of 1% low-
melting-point agarose gel. The agarose was pipetted onto slides previously coated with 1% 
agarose. Slides were stored in the dark for 10 min before adding in pre-chilled lysis buffer 
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(2.5M NaCl, 100 mM EDTA, 10 mM Tris-HCl, 1% N-lauroylsarcosine) for 1 h. The slides 
were washed three times for five minutes with the electrophoresis buffer (300 mM NaOAc, 
100 mM Tris HCl, pH 8.3). Gel electrophoresis was performed at 20 V and 65 mA for 25 
min. The Comet slides were washed three times for 5 minutes with 0.4 M Tris-HCl 
solution (pH 7.5) and air-dried over night at room temperature. 1 mL of a solution 2 µg/mL 
of ethidium bromide was placed to each slide. The slides were then analyzed with a 
fluorescence microscope (Zeiss fluorescence microscope with ApoTome attachment-Axio 
Zoom V.16, ZEISS, Germany). A total of 45 cells/sample were scored to determine the 
average percentage of DNA damaged.  
 
5.3.3. Peptides binding 
Solutions containing 3.5 µM of human recombinant H2A, H2B and H3.1 proteins (New 
England Biolabs, UK) and 0.05, 0.1, or 0.25 mM RDC11, ODC2, ODC16 and ODC20 in 
PBS, were incubated at 37°C for 1, 6, 24, 48 h in the dark. The aliquots were then resolved 
in non-reducing 14% sodium dodecyl sulfate-polyacrylamide gels, for 90 min at constant 
voltage (125 V) and visualized by Silver staining (Silver Stain PLus Kit, Bio-Rad, Marnes-
la-Coquette, France). 
 
5.3.4. Western Blot analysis  
MKN45 cells were treated with the IC50 and IC75 concentration of metal-based compounds 
for 6, 24, 48, 72 h. In some experiments, the pre-treatment with NAC (2 mM for 30') was 
carried out in order to detect the impact of the oxidative stress inducted by the compounds 
in the histones expression.  To extract the proteins, RIPA buffer (150 mM sodium chloride, 
1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS 50 mM Tris, pH 8.0, 1x protease 
inhibitor cocktail-Roche Diagnostics, Mannheim, Germany) was preferred for the nuclear 
fraction, whereas for the whole extract NP40 buffer (150 mM sodium chloride, 1.0% NP-
40, 50 mM Tris, pH 8.0, 1x protease inhibitor cocktail-Roche Diagnostics, Mannheim, 
Germany) was used. Debris was pelleted by centrifugation for 20 min at 14,000  x g at 
4 °C, and protein concentration of cell lysate was determined using Bio-Rad Dc Protein 
Reagents. Aliquots of 40 μg of each sample were electrophoretically separated by non-
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reducing sodium dodecyl sulfate-polyacrylamide gel (SDS-PAGE) 12 % and transferred to 
the nitrocellulose membrane. After blocking for 1 h at room temperature in 5% milk in 
Tris-Buffered Saline and Tween 20 (TBS-T), membranes were incubated with the antibody 
for H2A and H2B histones (Santa Cruz Biotechnology Inc., Texas, USA.), acetil-K9-H3 
(Abcam, Paris, France), H3 histone and cleaved caspase-3 (Asp175) (Cell Signaling, 
Beverly, MA, USA). Membranes were then washed 3x with TBS-T before being incubated 
with appropriate horseradish peroxidase conjugated secondary antibodies.  
 
5.3.5. Protein immunoprecipitation 
For the immunoprecipitation, 100 μg of protein extracts were diluted in RIPA buffer and 
incubated at 4 °C overnight with 2 μg/ml of H2A or H2B antibody (Santa Cruz 
Biotechnology Inc., Texas, USA). After incubation, 30 μl of protein A-Agarose (Sigma) 
were added to the reaction mixture and rotated for 1 h at 4 °C. Moreover, as negative 
control, purified rabbit IgG (Sigma) was mixed with the protein A. Immunoprecipitates 
were collected, by centrifuging at 500 x g for 5 min, and washed with the RIPA buffer  
three times. All proteins that adhered to the protein A beads were separated by mixing with 
30 μL of Laemmli buffer 2X and boiling the beads for 5 min. Samples were then 
centrifuged at 5000 x g for 1 min to pellet the agarose beads, and supernatants were 
analyzed by 12 % SDS–polyacrylamide gel electrophoresis and electrophoretically 
transferred to the nitrocellulose membrane. After blocking for 1 h at room temperature in 
5% milk in Tris-Buffered Saline and Tween 20 (TBS-T), membranes were incubated with 
the antibody corresponding to the histones H2A and H2B immunoprecipitated. 
 
5.3.6. Statistical analysis 
All data were presented as mean ± SEM. The statistical analysis was performed using 
Graph-Pad Prism (Graph-Pad software Inc., San Diego, CA) and ANOVA test for multiple 
comparisons was performed followed by Bonferroni’s test.  
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5.4 RESULTS 
5.4.1. Impact of organometallic compounds on cell viability 
The cytotoxic effect of metal-based compounds was investigated on the colorectal 
carcinoma HCT116 and the gastric adenocarcinoma MKN45 cell lines. The gastric cancer 
is the fourth most common cancer and the second most common cause of cancer death 
worldwide and more than 90% of gastric cancers are adenocarcinomas [Correa et al., 
2004]. It is considered one of the most difficult tumours to treat because of their frequency 
to show an innate or acquire multidrug resistance [Zhang et al., 2010; Hutchinson, 2012]. 
Since the tumours with low grade of differentiation are more aggressive [Jögi et al., 2012], 
the poorly differentiated MKN45 cells [Izuishi et al., 2000] can represent a good in vitro 
model to test the efficacy of organometallic compounds. The analysis of the dose-response 
curve obtained by MTT assay and the corresponding IC50 and IC75 values, showed 
remarkable antiproliferative effects with RDC11 and ODC2, also greater than that induced 
by platinum-based compounds (Fig.52 and table 4). In particular, cisplatin showed highest 
concentrations to inhibit the cell populations of 50% or 75%. As expected, MKN45 are in 
general less sensitive, but mostly on platinum compounds, whereas the effect produced by 
organometallics is noteworthy. The different structure of ODC16-ODC20 is responsible of 
a very high toxicity on both cell lines, so that the concentrations to inhibit of 50% the cell 
populations is in the nanomolar range; this pronounced difference in the cell viability 
confirms the importance of the structure-relationships in the activity of metal based 
complexes. 
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Fig. 52. Cell viability assay. Dose-response curves of HCT116 and MKN45 cell lines 
treated for 48 h with Cisplatin, Oxaliplatin, RDC11, ODC2, ODC16 and ODC20 at the 
indicated concentrations 
 
 
Tab. 4. IC50 and IC75 values (μM ± SEM) in the indicated cell lines following 48 h of 
treatment with metal-based compounds  
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5.4.2. DNA damage induced by organometallic compounds 
To better elucidate the effect of metal complexes on DNA damage, we analyzed its 
degradation by Comet Assay. This test, based on the higher electrophoretic mobility of the 
negativly charged DNA breaks [Olive and Banáth, 2006], allows detecting the immediate 
and direct impact on DNA in vivo, before the fragmentation due to the activation of 
apoptosis pathways. Thus, HCT116 colorectal carcinoma cells were treated for 1 h with 10 
or 25 μM of RDC11, ODC2, ODC16, ODC20. As shown in the microphotographs 
(Fig.53), a significant dose-dependent increment of DNA breaks occurs after treatment 
with RDC11 and ODC2. Interesting, when the cells are pre-treated with the antioxidant 
NAC, the damage is partially reverted. This means that in the early events leading to the 
DNA damage during treatment with organometallics the induction of oxidative stress is 
also involved, even if only in part. In particular, it can be estimated that the oxidative DNA 
damage represents about the 40% for RDC11 and 30% for ODC2 of the total DNA 
damage. On the other hand, ODC16 induces no significant DNA damage, whereas ODC20 
provokes just a little percentage of fragmentation. The lack of DNA damage, found also 
changing the parameters of the treatment, such as the time of incubation and/or the 
concentrations, seems to be in contrast with the high cytotoxicity that these compounds 
have proved by the viability assay. Nevertheless, the atypical activity of the ODC16 and 
ODC20 may depend mainly on a different profile of ligand-substitution reaction, cellular 
uptake and macromolecules affinity; for this reason, they need further investigation to 
individuate the basis of their high antiproliferative effect.  
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Fig. 53. Comet assay on HCT116 cells. Representative microphotographs of cells 
untreated (CT-), treated with positive control H2O2 (CT+), treated with RDC11, ODC2, 
ODC16, ODC20 without (A) or with (B) NAC and statistical analysis referred to an 
average of 40 cells per conditions. 
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5.4.3. Binding of organometallic compounds to histones 
Data in literature showed the importance of chromatin reorganization in the drug response 
activation [Jiang and Pugh, 2009], as well as the possibility of protein targets in the 
chromatin [Wu et al., 2011; Singh et al., 2014]. In addition, it is reported that there is 
specific sequence in the histones capable of binding the metals [Nunes 
 
et al., 2010; Bal et 
al., 2000; Midorikawa et al., 2005; Zoroddu et al., 2010; Bal et al., 1995].  
Here we reported the in vitro binding of the peptides H2A, H2B and H3 with different 
concentration (0.05, 0.1, 0.25 mM) of RDC11, ODC2, ODC16, ODC20 for 1, 6, 24 or 48 
h. In general, the treated histones migrate slower and with a more diffuse pattern, 
suggesting the presence of higher molecular weight proteins, due to the interaction with the 
organometallics. Also a shift in the height of monomers is visible, suggesting that the 
excess of histones remaining in monomeric form is bound to the metals. At 48 h of 
treatment of H2A with RDC11, it is clear the formation of dimers and trimers, while with 
ODC2, the trimers are less (Fig.54). Moreover, if on one hand the polymerization of H2A 
increases in a dose-dependent way, on the other hand the polymerization of H2B decreases 
with the higher concentration of treatments, especially with RDC11, proving a faster 
kinetics of action that finally could lead in histone degradations (Fig.54). In fact, by 
performing a time-course RDC11 treatment of H2B at shorter time (1, 6, 24 h), this histone 
showed a linear increase of polymerization over time and dose-dependent (Fig.55).  
In the case of H3, the time-course showed a shift in the migrations of the treated 
monomers, the fastest kinetics of polymerization with a presumably subsequent massive 
degradation and, unlike H2A and H2B, a marked polymerization in the control (Fig.55). 
Being H3 the only histone with sulphydryl groups that could form disulfide bonds, it's 
plausible that, in accordance with the data present in literature [Wood, 2006; Garrard et al., 
1977], it auto-assembles in non reducing conditions and that is more susceptible to the 
oxidation. Therefore the oxidation-reduction potential of these compounds may be the 
basis of their ability to induce phenomena of co-protein aggregation, and also explain the 
fact that, at the same dose and times of treatment with RDC11 and ODC2, which differ 
only in the metal center, they cause different degrees of aggregation.  
Conversely ODC16 and ODC20 time-course showed a very bland binding to H2B and H3 
(Fig.56), which remain in prevalent form of monomer, except for the treatment with the 
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higher concentrations of ODC20 after 24 h. At the same time, the H3 degradation is not 
present. These results can be correlated with those obtained in comet assay. For instance, it 
is interesting to see that the compounds that induce more DNA damages (RDC11, ODC2) 
are the ones that interact the best with histones, while the compounds interacting less with 
histones (ODC16 and ODC20) induces also less DNA damages although showing high 
cytotoxicity. Hence, it is tempting to hypothesize that part of the DNA damage seen in 
vivo could be caused by the interaction between the compounds and histone through a 
destabilization of the nucleo-DNA complexes. In addition it also indicates that ODC16 and 
ODC20 that are the most cytotoxic do not have the same mode of action, which remains to 
be identified.  
The atypical behavior of these compounds depends clearly on the ligand functions, and 
their analysis could help to clarify the structure-activity relationship also of other 
components of this class of metal compounds. All together, these data showed a great and 
diversified kinetics of histones interaction that requires a deepening in cell models, to 
investigate their implication in a physiological and biochemical environment.  
 
 
 
Fig.54.  H2B and H2A binding. SDS-PAGE of H2B and H2A histones incubated for 48 
with different concentrations (0.05, 0.1, 0.25 mM) of RDC11 and ODC2 compounds.  
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Fig.55. Time course of H2B and H3 binding. SDS-PAGE of H2B and H3 histones 
incubated for 1, 6, 24 h with different concentrations (0.05, 0.1, 0.25 mM) of RDC11.  
 
 
Fig.56. Time course of H2B and H3 binding. SDS-PAGE of H2B and H3 histones 
incubated for 1, 6, 24 h with different concentrations (0.05, 0.1, 0.25 mM) of ODC16 and 
ODC20 compounds.  
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5.4.4. Modification of H2A and H2B expression patterns in cells treated with 
organometallic compounds 
To assess whether the aggregation of histones H2A and H2B evaluated in the experiments 
with purified histones also occurred in cellular models, western blot analysis of H2A and 
H2B expression was performed in non reducing conditions. Since more bands were 
detected, the cellular extracts were subjected to immunoprecipitation, in order to reduce the 
background. It was possible to estimate an increment of aggregation in a similar way to the 
"in vitro" binding experiments; however, in this case it is possible that the bands are homo-
multiples or hetero-multiples, due to the binding with other histones forming the octamer. 
In addition, it is likely that in the complex intracellular environment the compounds 
interact also with other targets and it is difficult to assess in such complexity what would 
be the contribution of the interaction with histones. Also, additional mechanisms of histone 
modifications occurring in vivo are likely to impact on their expression level, 
polymerization status, post-translational modifications, and therefore altering their 
migration pattern.  
In particular, H2B showed just a little increase of polymerization (Fig. 58), whereas for 
H2A both monomers and its multiple resulted increased (Fig.57), except for the higher 
treatment of RDC11 and ODC2, for which the significant decrease of monomers is 
contextual with the relevant augment of their multiples. Thus it seems that the histones can 
be regulated in two different ways, leading to the general increase of expression, or to an 
induction of aggregation by a not yet known specific reaction. Moreover, in general the 
rapport polymerization/monomer is higher for RDC11 and ODC2 than for the platinum 
compounds. Interesting, unlike the experiments with purified histones, these results 
showed a stronger alteration of H2A migration pattern, meaning that, in the presence of all 
the histones forming the octamer, H2A is a favorite target or is more susceptible to the 
redox activity of the organometallics. Also, the presence of another band of H2B slightly 
higher than the monomers is relievable; it may represent presumably a post-translational 
modification, like acetylation, that of course, needs to be confirmed by using a specific 
antibody to detect this form. These results showed that also in the cancer cells the 
interaction between histones and metal-based compounds occurs, but with different 
profiles, that reflects the effect of the physical and biochemical microenvironment on the 
different ligand substitution reactions and redox potential.  
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Fig.57. H2A immunoprecipitation. H2A expression in MKN45 cells, after treatment with 
IC50 and IC75 of cisplatin, oxaliplatin, RDC11 and ODC2 for 24 h. 
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Fig.58. H2B immunoprecipitation. H2B expression in MKN45 cells, after treatment with 
IC50 and IC75 of cisplatin, oxaliplatin, RDC11 and ODC2 for 24 h. 
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 5.4.5. Modification of H3 expression pattern in cells treated with organometallic 
compounds 
In the cells the histones are the subject to multiple modifications that modulate their 
association with DNA, DNA compaction and also their translocation into the cytoplasm 
[Chen et al., 2014]. To evaluate how the organometallic interaction with histones impacts 
in the cells, the analysis of H3 expression by Western Blot was performed. MKN45 cells 
were treated for 24 h with IC50 and IC75 concentrations of RDC11 and ODC2, and also 
with cisplatin and oxaliplatin. Two kinds of buffer of protein extraction were used: the 
blander NP40 buffer, and RIPA buffer, more specific to extract the histones tightly 
attached to DNA (the nuclear fraction of H3) [Holden and Horton, 2009]. In these 
conditions, we found two different patterns of H3 histones, suggesting of a soluble fraction 
in the first case, and of a less soluble fraction, bound to the DNA, in the second case. 
While the less soluble fraction is uniformly and highly expressed in each sample, the 
soluble fraction of H3 is present prevalently in the treatments, and increases with the 
concentrations of these (Fig.59A). Interesting, when the cells are pre-treated with the 
antioxidant N-acetylcysteine, the increment of soluble H3 is completely reverted 
(Fig.59B). It therefore tempting to hypothesize that, as well as it happens in "in vitro" 
binding experiments, the oxidation of H3 by metal compounds occurs, provoking a 
massive detachment of this histone from the DNA, and its possible translocation in the 
cytoplasm.  
In this context, recent discoveries about the role of "free" histones are remarkable. It is 
believed in fact that when histones translocate from the nucleus to the cytoplasm and then 
to extracellular space, can act as signals for different pathological conditions, among which 
the apoptosis [Chen, 2014]. In particular, after a damaging on DNA, H3 can translocate 
and bind the mitochondria, influencing its function and ultrastructure, thus inducing a rapid 
and extensive release of the pro-apoptotic proteins cytochrome c and Smac/DIABLO 
[Cascone et al., 2012]. Thus it may serve as an amplifier of the apoptotic response. Also, 
the response to the antioxidant is stronger with organometallic compounds than with the 
classical platinum compounds, suggesting that while the redox activity, probably 
responsible for the direct oxidation of H3, is essential for the activity of organometallics, it 
is not the only component in the platinum compounds mechanism that leads to the 
separation of H3 also in an indirect way, perhaps due to the DNA binding. 
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Fig.59. H3 expression. Western blot analysis of H3 histone in MKN45 cells after 
treatment with IC50 and IC75 of cisplatin, oxaliplatin, RDC11 and ODC2 without (A) or 
with (B)pretreatment with NAC. 
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5.4.6. Caspase-3activation 
Stressing factor, such as ROS production, viral infection and chemotherapeutic agents, can 
lead to cell death by apoptosis. This process, starting with the amplification of signaling 
pathways, culminates with the DNA fragmentations and the formation of apoptotic bodies, 
rapidly removed by phagocytic cells [Savill and Fadok, 2000; Kurosaka et al., 2003]. In the 
scenario of the late state of apoptosis the reversion of nuclear components in the cytoplasm 
could occur. To evaluate the conditions in which the histone H3 translocation is detected, 
we thus analyzed the caspase-3 activated fragments as a marker of apoptosis.  
Surprisingly, the patterns of caspase 3 fragments induced by ODC2, RDC11 and platinum-
based compounds were different, highlighting again a different mode of action. As showed 
in Figure 60, for RDC11 and ODC2, high fragments of caspase 3 (about 25 kDa respect to 
17 kDa of the main activated form), that are presumably forms of a bland activation of 
caspase-3, were clearly observed at 24 h, but surprisingly, not latter. Inversely and more in 
line with the literature, high and lower fragments were progressively observed after 
treatment with cisplatin and oxaliplatin starting weakly at 24 hours. This result indicated a 
lack of correlation between the ability of the compounds to induce caspase 3 cleavage and 
the presence of more soluble H3. It also questioned the ability of RDC11 and ODC2 to 
induce completely apoptosis in these cells. Anyhow, it suggests that the cause of an 
increase of soluble fraction after treatment with the cytotoxic compounds is likely to be 
independent from the apoptosis process.  
A study on different cancer cell lines supports the idea [Wu et al., 2002] by describing that 
apoptotic cell lines showed release of histones from nuclei, but this event not necessarily 
coincides with the presence of fragmentations. In fact, not all cell lines release histones 
from nucleosomes during DNA fragmentation and apoptosis, and histones release and 
DNA fragmentation can be clearly separated into two independent processes. Thus it is 
plausible that the H3 translocation observed in our conditions is an early event preceding 
the cytotoxic process, apoptotic or not. This hypothesis is in accordance with the evidences 
about the destabilization of the outer and inner mitochondrial membranes (with subsequent 
release of pro-apoptotic proteins) due to the DNA damage-mediate histones release 
[Cascone et al., 2012]. Moreover, some studies showed the detection of histones in 
lymphoblasts lysates in a premature state of apoptosis, before also the exposition of PS on 
their cellular membranes [Gabler et al., 2004 and 2003].  
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Fig.60. Caspase-3 activation. Western Blot Analysis of cleaved-caspase-3 in MKN45 
cells untreated and treated with IC50 and IC75 of cisplatin, oxaliplatin, RDC11, ODC2 for 
24, 48 and 72 h. 
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5.4.7. H3-acetylation 
As widely discussed above (par.1.1.3.), the term epigenetic is referred to the protein 
modifications that lead to changes in gene expression; this process has a central role to 
control the cell proliferation and metabolism and could be a crucial point of regulation in 
the anticancer therapy. In this field, there is a wide report in literature about the important 
role of H3 histone acetylation in the gene regulation [Ganesan et al., 2009], that can lead to 
the expression of pro-apoptotic factors [Glozak and Seto, 2007]. In order to understand if 
RDC and ODC compounds impact the histones only by a direct binding, or also indirectly 
by induction of post-translational modifications, the acetylated form of H3 was detected by 
Western Blot analysis.  
As showed in Figure 61, an increment of acetylation both at fast time of incubation (6 h) 
and more (24 h) was found, even if with different kinetics for each compound. Generally, 
while at 6 h the acetylation is more with IC75 concentration of cisplatin, oxaliplatin and 
ODC2, at 24 h it increases with the IC50 treatment; this difference is especially strong with 
ODC2 treatment, showing an important dose/time/stimulus correlation; in fact, it seems an 
early process inducted by the compounds at right stimulus-concentration (IC50 conc. at 6h), 
not present in the extreme condition (IC75 conc. at 24 h), whereas the downstream 
activation of gene expression could occur. Conversely, induction of acetylation by RDC11 
rises over time with the higher concentration of the compound. However, these findings 
need further investigations to understand the relevance of this post-translational 
modification on the induction of specific gene expression. These considerations assume 
more relevance again in view of the extensive literature data about the epigenetic 
alterations present in gastric cancer type, among which a strong decrease of acetyl-H3, 
leading to an inhibition of gene expression [Muratani et al., 2014; Kang et al., 2014; Yang 
et al.,2014]. 
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Fig.61. Acetyl-H3 expression. Western blot analysis of acetylated form of H3 histone in 
MKN45 cells after 6 and 24 h of treatment with IC50 and IC75 of cisplatin, oxaliplatin, 
RDC11 and ODC2. 
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5.5. CONCLUSIONS 
Recently, anticancer agents based on alternative transition metals to platinum have 
emerged for their good cytotoxic profiles joined with fewer side effects and no resistance 
phenomena. On the other hand, the drawback of these new candidates is the lack of 
information on their mechanism of action, which is strictly correlated with the chemical 
characteristic of the structure and thus typical for each compound. Generally, ruthenium 
derivatives, among which RDC11, have shown a weak interaction with DNA, suggesting 
that other macromolecules can be preferentially their targets. Among these, the histones 
have emerged; they, allowing the different chromatin condensation states, have a crucial 
role in the DNA replication, transcription and repair. For these reasons, epigenetic 
modifications on histones are object of studies to elucidate their role in the activity of 
anticancer drugs. We have thus investigated if histones represent targets of the ruthenium 
derivate RDC11 and in the osmium derivates ODC2, ODC16, ODC20. All together, the 
data have shown a direct binding of organometallics with the histones, joined with a 
peculiar ability to provoke protein polymerization, events that could strengthen the 
chromatin perturbation. The hypothesis that the interaction with the histones could 
participate in causes of the DNA damage is tempting and might be supported by the 
different behavior of ODC16 and ODC20, for which the lack of histones binding 
corresponds with a poor induction of the DNA damage (Table 5). However, they showed 
high antiproliferative activity and need more investigations to understand their activity.  
 
Tab.5. Comparison between the IC50, the DNA damage induction and the histones 
iteractions of RDC11, ODC2, ODC16 and ODC20. 
On the other hand, the DNA damage inducted by RDC11 and ODC2 is marked and 
depends partially on the oxidative stress inducted; thus is probable that also the histones 
interaction is due to their redox potential, as demonstrated by the different capacity to 
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interact with the histones of RDC11 and ODC2, compounds that share the same organic 
structure. Therefore these results are in accordance with the previous showed for RDC11, 
about the crucial role of the oxidative stress and ROS production in its mechanism of 
action [Vidimar et al., 2012]. The oxidative stress seems to have an impact also on the 
oxidation of the histone H3, that not only could lead to the chromatin stress and thus to the 
DNA damage, but also in H3 translocation, event that recently was found to be crucial in 
several stress signaling pathways. Also, the treatment with organometallics induces H3 
acetylation, which is a key-event in the regulation of gene expression, for example 
inducing the transcription of pro-apoptotic genes [Glozak and Seto, 2007] (Fig.62). These 
promising results need thus further investigations to evaluate the impact of the 
organometallic interaction with histones on the chromatin, as well as to individuate the 
specific genes that are regulated by H3 acetylation.     
 
 
Fig.62. Mechanism proposed for the role of epigenetic targets in the RDC11 and ODC2 
mechanism of action: the compound (in red) can impact on the chromatin (in green) 
structure  by direct binding, induction of histones polymerization (in pink), induction of 
acetylation (Ac) and H3 translocation. The extranuclear H3 could induce intrinsic 
apoptosis, as well as act as extracellular signal of cell death. 
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Cancer is the second leading cause of death. Although it is already validated the use of 
techniques such as radiotherapy, immunotherapy and chemotherapy, in the last decade the 
medical community has focused on the research of less invasive drugs, through the 
identification of new anticancer agents, as well as by the design of innovative systems for 
the drug delivery, like the liposomes, that allow the protection of the active principle until 
the achievement of molecular targets, reducing the toxic effects. Among the new 
anticancer agents currently in clinical trials, there are the ruthenium-based compounds, 
NAMI-A and KP1019 [Sava et al., 1998; Kersten et al., 1998], which have emerged as 
promising alternatives to platinum compounds, because of their great anticancer and/or 
antimetastatic activity, associated with fewer side effects. The difference between the 
derivatives of ruthenium and platinum is probably due to their different pharmacodynamics 
that, if is well known for cisplatin and its analogs, it is not yet completely clarified for the 
other metal complexes. Also, chemical characteristics like the redox potential, the charges 
and the lipophilicity are very different among the various classes of metal-based 
compounds, reflecting their different biological effects. In fact, while KP1019 is 
considered prevalently an anticancer agent, NAMI-A is prevalently an anti-metastatic 
compound, probably because it interacts more with extracellular components [Brescacin et 
al., 2015; Pelillo et al., 2015]. The low molecular weight AziRu [Mangiapia et al., 2012], is 
an analog of NAMI-A, in which, instead of the imidazole, there is the pyridine. This 
substitution gives more lipophilicity to the complex, which thus should more easily interact 
with the cell membranes; in fact, the IC50 values relative to AziRu are lower than those 
calculated for NAMI-A. However, the values are still too high to be considered an 
anticancer agent. Also, this generation of low molecular weight ruthenium complexes, is 
not stable in physiological solution.  
In this context, my Ph.D. was aimed to the in vitro characterization of different classes of 
new metal-based compounds. First of all the interest of this work was to evaluate their 
anticancer activity as well as their safety. Subsequently, the study was focused on the 
identification of the kind of cell death pathway induced by these compounds and their 
specific targets, in order to clarify their mechanism of action. The first tested class belongs 
to a new nanotechnological platform in which different kinds of liposomes contain AziRu. 
These drug delivery systems represent thus an innovative evolution of the ruthenium 
complexes, improving both chemical and biological profiles. In particular, AziRu is bound 
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to a nucleolipid acting as central scaffold, in which different substituents can be inserted, 
among these the lipophilic chains allowing the self-assembly. These nucleolipids based-Ru 
are prepared in co-aggregation with neutral (POPC) or cationic (DOTAP) lipids, in order to 
improve the stability of the aggregates. In fact, the ruthenium-based liposomes have shown 
good stability both in water and physiological solutions, as well as an important reduction 
of the IC50 values (whereas the free-ruthenium liposomes are not cytotoxic), proving the 
efficacy of the "nanovectorization" on the explication of the anticancer effect of 
ruthenium-based compound AziRu. In particular, the cationic formulations with the lipid 
DOTAP have shown more efficacy than the previous investigated neutral liposomes 
[Mangiapia et al., 2012], both in term of antiproliferative effect, than in term of cellular 
uptake. Thus, the coupled results of the cell viability and of the cellular uptake showed that 
the cationic liposomes are a good system to deliver the ruthenium complexes, probably due 
to the greater interaction between the cationic lipid and the negative component of the cell 
surface, such as proteoglycans [Wiethoff et al., 2001]. Moreover, we demonstrated that the 
cationic liposomes induce both autophagy and apoptosis, suggesting the activation of 
multiple pathways of cell death, perhaps due to the binding of targets in different cellular 
compartments.  
Subsequent modifications of neutral and cationic nanovectors have led to: 
i)ToThyCholRu/DOTAP, in which the liposome is functionalized with the cholesterol able 
to regulate the physico-chemical properties of lipid bilayers, in order to stabilize liposomes 
and to improve their cellular uptake; ii)ToThyRu/POPC/de-LOS, in which a modified 
lipooligosaccharide derived by the bacteria Rhizobium rubi is inserted into the liposomal 
bilayer to mimic the bacteria walls, thus exploiting its quality of resistance and stability, 
and at the same time the de-O-acylation avoids the recognition by the immune system and 
thus making it a good stealth system. These two formulations have been tested also on 
healthy cells, whereas either showed no significant activity. These results give support to 
the hypothesis of the ruthenium activation by reduction in cancer cells [Clarke et al., 
1999]. Since most anticancer drugs lack of cancer specificity and cause side effects on 
normal tissues, ruthenium complexes may provide a less toxic and more effective 
alternative to common chemotherapeutic agents.  
Overall, this tested mini-library of nanovectors demonstrated how it is possible, by ad hoc 
modifications of their structure, to modulate their chemical and biological characteristic 
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and thus make them appropriate for different applications. Also, these systems effectively 
improve the anticancer activity of ruthenium, as direct effect of the "nanovectorization", 
that in principle, could be applied also to to deliver in vivo a a large variety of lipophilic 
drugs, enhancing their long-life in the blood. Therefore, as well as these screenings have 
led to some important conclusions in the context of the characterization of a new 
nanotechnological platform of ruthenium-based compounds, these results lay the 
groundwork for further deeps both on the usability of these nanovectors as possible drug 
carriers and for the understanding the wide spectra of actions of the ruthenium-based 
complexes.  
Thus, the next goals of this study will be testing the specific targets involved in their 
mechanism of action that, as widely discussed, differ substantially for each compound, in a 
manner strictly related to their chemical and physical characteristics. In the last decade, a 
large number of chemical and biological investigations have been carried out in order to 
individuate the targets of metal compounds, showing that, beside the DNA [Bergamo and 
Sava, 2007; Brabec and Novakova, 2006], nuclear and cytosolic proteins could have a 
central role in the mechanism of action of ruthenium-based complexes [Mendes et al., 
2011; Casini et al., 2010]. Among these, the proteins binding DNA, the histones, have 
emerged [Davey GE and CA, 2008; Wu et al., 2011; Adhireksan et al., 2014; Singh et al., 
2014; Soori H., 2015]. These proteins, allowing the different chromatin condensation state, 
have a crucial role in the DNA replication, transcription and repair. In an attempt to 
elucidate this possible mechanism of action, the present Ph.D. research was then focused 
on the role of histones, and more in general of the epigenetics, on the class of N-C 
ruthenium and osmium heterocyclic compounds, named RDC11, ODC2, ODC16, ODC20 
[Gaiddon et al., 2005; Ryabov et al., 2003; Boff et al., 2013]. These compounds, in 
particular RDC11, are already chemically and biologically well characterized, showing a 
remarkable cytotoxicity in vivo and in vitro, whereas the activation of different pathways 
of cell death, as well as the induction of oxidative stress, were found [Gaiddon et al., 2005; 
Meng et al., 2009; Vidimar et al., 2012]. We found a different pattern of activity for the 
ruthenium- and osmium-derived compounds RDC11 and ODC2 respect to the second 
generation of osmium-derived compounds ODC16 and ODC20; in fact, these last 
complexes didn't induce a marked DNA damage, as well as didn't seem to strongly interact 
with the histones, despite their high cytotoxicity. Conversely, RDC11 and ODC2 showed 
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both to induce DNA damage (partially mediated by oxidative phenomena) and to interact 
with the histones. These results support the hypothesis that the DNA damage could be 
mediated by the direct interaction with the histones, as well as the different profile of 
ODC16 and ODC20 demonstrates the importance of the structure-activity relationship. In 
addition, some differences prevalently in term of kinetics of action, occur also between 
RDC11 and ODC2, compounds that share the same structures, and thus highlighting how 
the response to the metal drugs is correlated with the metal redox potential. Moreover, we 
found both the histone H3 translocation, an event that recently has been correlated with the 
stress signaling pathways [Chen et al., 2014], and the H3 acetylation, an important post-
translational modification, leading to the induction of specific gene expression, such as the 
pro-apoptotic genes [Glozak and Seto, 2007]. Since the different redox potential of the 
metals modulate the kinetics of histones binding, and the induction of oxidative stress is 
important for the DNA damage and the H3 translocation, we can hypothesize that the 
interaction of organometallic compounds with the histones is strictly correlated with their 
potential to induce oxidative stress. All together these data demonstrated that the histones 
could be crucial targets to mediate the cellular response to the organometallic compounds, 
and confirm also an important role of the epigenetics changes in their mechanism of action.   
Overall, this doctoral study, focused on the characterization of different class of metal-
based compounds, demonstrated that ruthenium and osmium complexes could be 
promising alternative to platinum compounds, as well as it has shown how the chemical 
modifications in their structure are responsible for different pharmacodynamics, remarking 
thus the advantage of their wide spectrum of action due to the important role of the 
oxidation/reduction state and the possibility of functionalization with different ligands.  
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